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ABSTRACT 
 Self-amplifying RNA replicons are an attractive alternative to traditional nucleic 
acid therapeutics, providing high, sustained expression from a low dose, without the risk 
of genomic integration. Replicons are derived from a viral genome, but utilize viral self-
amplification to produce heterologous genes instead of the structural proteins necessary 
to form virions. Despite a variety of therapeutic applications, ranging from vaccination to 
genetic reprogramming, regulating expression from replicons remains relatively 
unexplored, as the field continues to rely solely on constitutive expression. However, we 
will demonstrate that dose cannot be used to control constitutive expression levels from a 
replicon. Without any means of regulation, the inability to adjust expression is a major 
safety concern that must be addressed before this platform can be used for more 
clinically-driven specifications. 
 In this dissertation, we have employed synthetic biology to expand the potential 
of replicon-based platforms to include sequence-level and small molecule mediated 
control of expression levels. Synthetic biology aims to create and characterize libraries of 
highly predictable and modular genetic parts that can be combined to produce genetic 
circuits. To this end, we generated a collection of parts that can modulate replicon 
  vii 
subgenomic transcription, explored existing and novel replicon-based expression 
platforms, and designed small molecule responsive replicon circuits. We established 
sequence elements that can be used to predictably control constitutive expression levels 
of up to three genes driven from a single self-amplifying RNA strand. We verified that 
this regulatory framework was functional for multiple replicon-based platforms, 
including multi-SGP replicons, DNA-launched replicons, and a novel self-cleaving, 
amplifying RNA platform. Finally, we coupled these genetic parts with small molecule 
responsive elements to form RNA-only circuits delivered on a single replicon that could 
control expression of multiple proteins based on external inputs.  By introducing 
regulatory genetic circuits to self-amplifying RNA, we demonstrate control over the 
strength, timing, and location of expression, enhancing the utility of RNA for gene 
delivery and establishing a framework for the next generation of RNA-based 
therapeutics. 
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1. INTRODUCTION AND SPECIFIC AIMS 
 
 Self-amplifying RNA is quickly emerging as a promising platform for the 
delivery of gene-based therapeutics, providing sustained high expression compared to 
non-replicating RNA, without the risk of genomic integration associated with viral 
vectors. Traditional small molecule-based pharmaceuticals are limited by target 
druggability, and protein therapies suffer from decreased stability in vivo. Nucleic acids 
offer a robust, low cost platform with the potential to affect a wider range of therapeutic 
targets. While messenger RNA (mRNA) and plasmid DNA (pDNA) were shown to 
produce equivalent expression in mouse skeletal muscle more than two decades ago, 
pDNA has been the primary mode of nucleic acid gene delivery due to its stability and 
ease of generation
1
. Despite increased attention and involvement in numerous clinical 
trials, however, pDNA is still not licensed for human use. The inefficacy of pDNA is 
primarily attributed to inefficient delivery to the nucleus, requiring high dosages of 
pDNA in humans. Non-replicating RNA is an attractive alternative because it is 
translated in the cytoplasm and recent developments have significantly decreased the 
immune response triggered by synthetic RNAs. Nevertheless, non-replicating RNA has a 
relatively short half-life and low expression compared to other modes of nucleic acid 
gene delivery.  
 RNA replicons solve many of the intrinsic hurdles associated with pDNA and 
non-replicating RNA. Similar to non-replicating RNA, replicons are translated in the 
cytosol, unable to integrate, and only require transport through a single cellular 
membrane. Because replicons self-amplify, they have higher expression than non-
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replicating RNA, permitting the use of lower initial doses. Yet, with these advantages 
comes the need for additional characterization and engineering:  
 
Aim 1: Monitor replicon dynamics to ascertain methods to predictably modulate 
expression levels of multiple genes driven from self-amplifying RNA   
 
 Prior to this work, replicons were predominately used to constitutively express 
heterologous genes. We will demonstrate that self-amplification of a replicon results in 
saturation of protein expression, independent of the initial dose
2
. In this way, replicons 
differ from pDNA or non-replicating RNA, where changing the initial dose alters the 
copy number per cell and subsequently affects the amount of protein produced. While 
high expression from a low dose is beneficial, regulation of expression levels is essential 
for patient safety. To this end, we will establish a predictable, competition-based 
regulatory motif to control the levels of multiple constitutively expressed proteins from 
co-transfected replicon species. 
 
Aim 2: Design and characterize a novel set of replicon parts to control the 
expression levels of multiple proteins driven from a single replicon 
 
 Despite successful regulation of multiple constitutively expressed proteins, we 
will prove that co-transfection is an unreliable means of long term control of replicon 
expression. Additionally, co-transfection is challenging in vivo, although this is a major 
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focus of current drug delivery research. Based on these findings, the remainder of this 
work will focus on regulatory mechanisms that can be employed on a single replicon. We 
will begin by elucidating the factors that can affect expression of multiple genes from a 
replicon. Then, we will generate a parts library and devise a robust assembly strategy to 
comprehensively characterize constitutive expression of one, two, or three separate genes 
from a single self-amplifying RNA. Finally, we will use these studies to inform the 
design and construction of more complex RNA circuits in Aims 3 and 4.    
 
Aim 3: Develop single replicon circuits, with an emphasis on small molecule 
responsive OFF and ON switches 
 
 While the replicon parts library will offer sequence level control, to enhance the 
safety of our replicon platform we will also introduce modes of external control. Small 
molecule regulatory devices, including the Tet-ON/OFF® or Rheoswitch®, have been 
well-characterized and used extensively in pDNA genetic circuits
3,4
. Yet, there exist very 
few RNA control devices
5–9
. Many of these, including short interfering RNA (siRNA) or 
aptazymes, regulate RNA via degradation-based mechanisms, and could not be used in a 
single replicon system because the entire RNA strand would be destroyed. Instead, we 
will employ a novel regulatory motif by fusing small molecule responsive domains onto 
RNA binding proteins (RBPs). Using these RBPs, in conjunction with the sequence-level 
control mechanisms from Aim 2, we will create a variety of small molecule mediated 
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OFF and ON switches to externally control expression of either one or two genes of 
interest.  
 
Aim 4: Expand this regulatory framework to other replicon-based expression 
platforms, including DNA launched replicons (DREPs) and an innovative self-
cleaving split Helper-Defective Interfering (DI) RNA system 
  
 Specifically, we will import our RNA control elements into another well-
established replicon-based platform launched from DNA
10–12
. We will demonstrate that 
DREPs not only follow the same design principles as RNA, but that they can produce 
equivalent expression to pDNA from much lower initial doses. Additionally, we will use 
our parts library and assembly strategy to optimize the production of a clinically relevant 
influenza antibody. 
 We will also introduce a pioneering platform in RNA therapeutics that can utilize 
both the sequence-level control developed for the replicon and previously established 
degradation-based regulatory mechanisms. This platform will be delivered to the cell as a 
single strand of RNA. Upon entry this RNA strand will self-cleave and each of its 
subunits will amplify separately. Thus, each subunit can be independently regulated using 
any available RNA regulatory devices without having an effect on the other.      
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2. BACKGROUND 
 
2.1 Small Molecule Pharmaceuticals 
 Small molecule pharmaceuticals have historically served as the most successful 
therapeutics
13
. Originally these drugs were created by finding a natural source with 
activity against negative agents, such as cancer cells or particular microorganisms. Once 
activity was observed, serial purification was performed to enhance this function until the 
active chemical compounds were obtained. Unfortunately, these chemicals were often 
complex and purification from the natural source was not always feasible due to either 
low quantities of the natural source or expensive purification processes. If it was possible, 
synthesizing and purifying these small molecules was still costly, time consuming, and 
low throughput. Furthermore, the underlying mechanism of action between the active 
compound and target remained unidentified. 
 The advent of solid phase synthesis proposed by Merrifield removed this rate-
limiting step
14
. While initially employed to rapidly create large quantities of peptides of 
any desired sequence, this technique was also applied to oligonucleotides and 
combinatorial assembly of small molecule pharmaceuticals, revolutionizing the 
industry
15,16
. Libraries of therapeutically relevant small molecules were generated against 
new targets by combining functional domains known to be active against specific protein 
motifs. Advancements in genomics, however, have begun to reverse this methodology. 
Now relevant target proteins are being discovered to which small molecule 
pharmaceuticals must be tailored. Many of these newly identified protein targets are not 
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enzymatic, i.e. their activity is not dependent on the presence of a ligand. Such targets, 
including regulatory or scaffolding proteins, typically rely on protein-protein interactions, 
and are difficult to affect using small molecules. The notion of “druggability” emerged, 
referring to whether a target protein can be affected by small molecules or must be 
approached by another means
17,18
. While small molecule pharmaceuticals will remain in 
the forefront of drug therapies as a result of their efficacy interacting with ligand-binding 
domains, such as those found in receptors and enzymes, and the ease of oral 
administration, they are not ubiquitous therapeutics and other options must be explored. 
 
2.2 Protein Therapeutics 
 Protein therapeutics have progressed dramatically following the tremendous 
success of recombinant human insulin and, unlike small molecule therapeutics, have the 
potential to target protein-protein interactions
19
. Protein therapies have been developed to 
restore deficient or dysfunctional proteins, to enzymatically degrade harmful extracellular 
targets, and to activate or inhibit cell surface receptors
20
. Monoclonal antibodies are 
particularly prevalent, as they can be used to specifically target surface proteins of 
diseased cells to either block function or induce an immune response. 
 Despite the wide variety of applications, protein therapeutics are limited by 
stability and immunogenicity
21,22
. Proteins typically cannot cross cellular membranes, 
affecting tissue accessibility for some applications. Moreover, proteins are exposed to 
proteases in the blood and those under 70,000 Da are subject to rapid clearance by the 
kidneys
23
. The decrease in efficacy caused by degradation and clearance is overcome by 
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increasing dose, adding to the already high production and purification costs of protein 
therapeutics compared to small molecule pharmaceuticals. While it is possible for 
proteins to have longer half-lives than small molecules in vivo, dosing is more labor 
intensive. Proteins cannot be delivered orally because they are rapidly degraded in the 
intestines. Instead, they must be administered intravenously, requiring multiple visits to a 
clinic, unless a delivery system is readily available, as it is for insulin. 
 Many of the aforementioned drawbacks associated with protein therapies are 
being addressed and eliminated. PEGylation is being used to decrease clearance and 
increase protein half-life
24,25
. Enhanced understanding and prediction of protein 
glycosylation is decreasing immunogenicity while improving functionality
26,27
. Novel 
nanoparticle and lipid-based delivery systems are being developed to allow intracellular 
protein transport; this could drastically improve efficacy and lower the required doses
28–
31
. Additionally, intracellular delivery would vastly increase the potential therapeutic 
targets, previously limited to those exposed on the cell surface. Yet, it does not appear 
that the cost of protein production and purification will decrease enough in the near future 
to compete with small molecule pharmaceuticals. Nucleic acids may offer similar 
benefits at a fraction of the cost. 
 
 
2.3 Nucleic Acid Therapeutics        
 Nucleic acids have shown promise as an alternative to protein therapeutics for a 
number of applications, including vaccination, cancer immunotherapy, genetic 
reprogramming, and protein-replacement therapies
32–34
. Nucleic acid therapies avoid the 
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high costs associated with protein therapeutics by producing the desired protein within 
the target cells, allowing for correct folding and protein modifications, as well as longer 
exposure to the therapeutic protein
35
. The proteins produced can affect either intracellular 
or extracellular targets by introducing secretion signals. While targeted protein delivery is 
primarily extracellular via modified liposomes, nanoparticles, or protein-protein 
interactions, nucleic acids have the ability to determine cell specificity inside the cell 
using genetic parts, such as tissue-specific promoters or microRNA (miRNA) target 
sites
36–38
. This intracellular control, which can be coupled with extracellular modes of 
targeted delivery, is one of the key benefits of nucleic acid therapies, although the use of 
such therapies in a clinical setting is still very much in its infancy. 
 DNA, the primary delivery platform for nucleic acid therapies, is generally 
introduced as either a viral vector or plasmid DNA (pDNA). Viral vectors have a 
stigmatic past, with risks of severe immune responses and oncogenicity due to undesired 
integration
39,40
. One of the most promising and well-studied viral vectors, adeno-
associated virus (AAV), was approved for human use in Europe in 2012 for a rare genetic 
disease
41
. Even AAV, however, has limitations. Because of the prevalence of AAV in 
humans, a large percentage of the population has antibodies against one or more AAV 
serotypes. These antibodies can cross react and neutralize other AAV serotypes, requiring 
researchers to develop unique AAV platforms
42–45
. It follows, and has been demonstrated, 
that repeat administration of the same AAV serotype results in significantly decreased 
expression
46,47
. AAV also has a payload limit of 4.7 kilobases, which can be doubled with 
trans-splicing, but at the cost of expression level
48,49
. Multiple AAV species can be co-
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transfected to express two genes, but there is currently no mechanism available to control 
the relative expression levels of each. Finally, while AAV has low immunogenicity 
compared to other viral vectors, it has been shown to elicit both a humoral and cell-
mediated immune response
50–53
.  
 Additionally, while production and assembly costs for nucleic acid therapeutics 
are inexpensive, creating viral particles requires the use of cell culture methods. This 
added step not only increases cost and biosafety level, but can also potentially introduce 
biological contaminants
54
. Furthermore, the viral particles produced are not as stable as 
naked nucleic acids, and, in many cases, particle production results in titers that are too 
low for industrial scale
55
. 
 Plasmid DNA, on the other hand, is stable, cheap, and has a much larger 
packaging size than AAV or viral vectors, without the possibility of a pre-existing 
immunity or safety concerns resulting from the potential for biological contamination. 
The cost to synthesize and sequence DNA continues to decline
56
, and innovative methods 
of DNA assembly
57–60
 have enabled more complex design.  
 DNA regulatory devices have been engineered to respond to external stimuli, such 
as small molecules or blue light
3,61–64
. Coupling these devices with other transcriptional 
activators and repressors has facilitated the design of intricate genetic circuits in 
mammalian systems, including a bandpass filter
65
, time-delay
66
, and Boolean logic 
gates
67
. As an alternative to external inputs, endogenous promoters and miRNAs have 
been used in conjunction with logic gates to target specific cell types, such as cancer 
cells, and elicit a response
68,69
. The low cost, ease of assembly, and wide availability of 
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genetic parts has made pDNA a vital platform for engineering synthetic circuits.        
 However, because it lacks viral packaging, delivery is a major hurdle for pDNA 
in becoming an effective treatment strategy. In order to express, pDNA must enter the 
nucleus, restricting its use in vivo to dividing cells, in which the nuclear membrane breaks 
down during cell division
70,71
. As previously noted, despite its involvement in numerous 
clinical trials, pDNA has yet to be approved for human use. Many pDNA therapies show 
promise in smaller mammals, but the high dose required does not scale for use in 
humans
54
. Aside from difficulties with delivery, pDNA is also subject to epigenetic gene 
silencing, affecting long term expression of a therapeutic protein
34,72,73
. Finally, pDNA 
has copy number dependent expression. Because pDNA cannot normally replicate, if 
more copies enter a given cell, then the cell will produce more protein. While this allows 
for mean protein levels to be controlled by altering initial pDNA dosage, it also 
introduces variation, depending on the delivery method
74,75
. As expected, copy number 
dependent expression is also observed using non-replicating RNA, but as we will show, 
this is not the case with replicons. 
 Non-replicating RNA has recently emerged as a potential therapeutic platform, in 
part, due to the development of novel modifications that decrease immunogenicity and 
increase RNA half-life
35,54,76
. Unmodified mRNA has been shown to express in vivo as 
long as a week, but results in a significant innate immune response
77,78
. By incorporating 
modified bases, such as pseudouridine and 5-methylcytidine, into the mRNA, expression 
has been observed up to 4 weeks with a diminished innate immune response
79–83
. 
Additional optimization of the 5’ cap, untranslated regions (UTRs), poly-A tail length, 
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and open reading frame (ORF) have also been shown to affect mRNA stability and 
expression
35
. Unlike transcription of pDNA, translation of modified RNA (modRNA) 
occurs in the cytoplasm, making transfection possible in both dividing and non-dividing 
cells. However, because modRNA cannot replicate, dilution becomes an issue in rapidly 
dividing cells. Additionally, modRNA generally has lower expression levels than self-
replicating RNA. Nonetheless, many of the genetic parts created for replicons can also be 
used with modified mRNA, and for some applications a much lower immune signature 
may be preferable. 
 Replicons are self-amplifying RNA, capable of producing high amounts of 
protein expression up to seven weeks after administration in vivo, from relatively low 
initial doses compared to pDNA and non-replicating RNA
84
. Of the numerous replicon 
systems developed, we have chosen to study two replicons derived from the alphavirus 
genus, Sindbis virus (SIN) and Venezuelan Equine Encephalitis virus (VEE)
85–88
. 
Replicons from both of these viruses are well-characterized and variants with reduced 
cytopathicity have been established
89–91
. Alphaviruses are a group of positive-strand 
RNA viruses with genomes between 11–12 kilobases. The genome is divided into two 
parts: the 5’ two-thirds encodes four non-structural proteins used in RNA replication and 
the 3’ one-third, or subgenomic RNA, encodes the structural proteins92. The genome is 
preceded by a 5’-7-methylguanosine cap and ends with a 3’-poly(A) tail, mimicking 
cellular mRNA to facilitate translation of the non-structural proteins (nsPs) using host 
cell machinery. As shown in Figure 2-1, the non-structural proteins are translated to form 
a polyprotein replicase complex that transcribes a minus-strand intermediate early in 
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replication. The replicase is later self-cleaved into its individual non-structural proteins, 
enabling this minus-strand to be used as a template for production of both the full-length 
positive genomic and the subgenomic RNA. In a wild type alphavirus, the structural 
proteins would be translated from this subgenomic RNA and used to package the newly 
created positive-strand genomes. However, in a replicon, these structural proteins are 
replaced with engineered genetic parts or therapeutic proteins, preventing infection of 
other cells and creating a potent RNA gene delivery platform. 
 As self-replicating RNA, replicons offer several advantages over other nucleic 
acid delivery systems. Because replication occurs outside of the nucleus and replicons do 
not reverse transcribe, there is minimal risk of integration, a major concern with viral 
particles. In addition, replicons have shown low vector immunity, expanding its 
applications to those requiring multiple doses
93–95
. Replicons are also able to persist in 
both dividing and quiescent cells, presumably with lower dilution rates in rapidly 
dividing cells than non-replicating RNA
96
. A high dose of a therapeutic protein can also 
be produced from as little as one replicon entering a target cell, minimizing the impact of 
delivery efficiency compared to pDNA and mRNA. 
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Figure 2-1 The Alphavirus Lifecycle. The alphavirus replication cycle begins by translation 
of a polyprotein comprised of the four non-structural proteins (nsPs) using host cell 
machinery. This polyprotein transcribes the minus strand compliment early in replication. 
Later, nsP2 self-cleaves this polyprotein into its individual constituents. The separated non-
structural proteins transcribe, cap, and polyadenylate full-length positive strand RNA, as 
well as subgenomic RNA. In a virus, the structural proteins are translated from the 
subgenomic RNA. However, in a replicon, these proteins are replaced with heterologous 
genes for therapeutic applications. 
 
 
 
3. DYNAMICS AND CONTROL OF REPLICON EXPRESSION 
 
3.1 Introduction 
 Prior to this work, replicon systems were primarily used to deliver a single, 
constitutively expressed gene product
87,93,97
. While some approaches were proposed to 
express multiple gene products
98–101
, independent regulation of these products remained 
elusive. However, many applications require more sophisticated tuning, with multiple 
proteins expressed at controlled levels. These products many need to be separately 
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regulated or to regulate one another. Before constructing any regulatory circuits, we 
aimed to control constitutive expression levels from a replicon. Plasmid DNA and 
modRNA expression levels are easily tuned in vitro by modulating the initial transfected 
dose. Thus, we sought to use dose to control expression levels and saw co-transfection as 
the simplest way to express multiple proteins. 
 
3.2 Sindbis Replicon Dynamics 
 Because replicons self-amplify, we expected to observe a saturated expression 
level due to either cellular resource limitations or negative feedback evolved by the 
replicon
2
. By changing the initial dose and observing replicon expression over time we 
thought that we could quantify the effect of dose on both saturation level and the time 
required for saturation (Figure 3-1A/B). That being said, changes to the initial dose over 
two orders of magnitude had no effect on either the level or timing of saturation (Figure 
3-1C/D). Expression was dose-dependent during the first 11 hours post-transfection, but 
by 16 hours, protein expression converged and remained at the same saturated state for 
all doses. These results were promising because they showed the replicon’s potential to 
elicit a large response from a very low dose, but precluded dose as a means to tune 
protein expression levels. While dose also has effects on transfection efficiency, with 
lower doses resulting in fewer transfected cells, those cells that do receive a replicon 
exhibit saturated expression levels (Figure 3-1E). 
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Figure 3-1. Dose Response of Constitutive Replicon Expression (A-B) Hypothetical curves 
illustrating how dose could vary saturation level and/or the time required for expression to 
saturate. (C) Constitutive expression of mVenus versus time for doses over two orders of 
magnitude, showing a rapid increase to a dose-independent level. Dose is indicated by hue, 
ranging geometrically from 21 ng (magenta) to 2055 ng (yellow). (D) The same data shown 
for the first 11 hours post-transfection, highlighting the dose-response during this period. 
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(E) The fraction of cells expressing over time versus dose shows that decreasing dose 
decrease the percentage of cells transfected, and vice versa. Cells that are transfected, even 
from low doses, still exhibit saturation of expression. All data were gathered using Sindbis 
replicons electroporated into BHK-21 cells. Expression units are MEFL: Molecules of 
Equivalent FLuorescein. 
 
3.3 Regulation via Co-Transfection 
 It is possible to avoid competition between two co-transfected species when 
delivering modRNA or pDNA. A single species of modRNA transfected alone or co-
transfected with another modRNA will express at the same level, assuming the dose is 
low enough to prevent competition for translational machinery. In the same way, genes 
from two plasmids will express independent of one another, unless there is a means of 
competition, for instance if both genes are driven by the same promoter. Because all 
Sindbis replicons utilize the same nonstructural proteins and saturation points to high 
expression levels inside the cell, competition between multiple replicon species was 
expected. And indeed, while the total fluorescence from two co-transfected replicons 
remained constant, a change in the initial ratio of the two transfected species resulted in a 
linear change in expression (Figure 3-2). The constant total fluorescence indicated that 
co-transfection could not be used to exceed the saturation limit of a single replicon. 
However, competition could be a means to tune down expression from a replicon. For 
example, to regulate expression from a single replicon of interest, a second “ballast” 
replicon could be added to the system to decrease the expression of the desired protein in 
a linear, competition-dependent manner.   
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Figure 3-2. Using Competition to Regulate Expression from Co-transfected Replicons (A) Co-
transfection of two replicons at varying ratios and a constant combined dose produces a 
linear relation between relative dose and fluorescence and (B) constant total fluorescence. 
BHK-21 cells were transfected with pairs of replicons that are identical except for the 
fluorescent reporter: mVenus/mKate, mKate/EBFP2, or mVenus/EBFP2.  Each sample was 
transfected with 1390 ng total RNA, at varying titrations of the two replicons ranging from 
0% to 100% in steps of 10%. Fluorescence was measured 20 hours post-transfection 
Expression units are MEFL: Molecules of Equivalent FLuorescein.  
 
 A mathematical model was generated to predict expression from one or more 
transfected replicons over time. The single replicon dose response time course was fit to 
the following: 
 
where E(t) is the expression at time t, S is the saturated expression level, δE is an initial 
delay representing the early phase of the exponential replication process, and λE is the 
time constant on the exponential convergence toward saturation at the translation limit. 
Figure 3-3A compares this model (fit to parameters S = 1.05 x 10
8
 MEFL, δE = 4.02 
hours, and λE = 5.86 hours) against all of the time points gathered through the first 26 
hours post-transfection, showing that it is indeed a good fit, with a mean geometric error 
  18 
of 1.07-fold between model and prediction. 
 When considering distribution of fluorescence, however, variation is much greater 
than can be accounted for only by a pure Poisson distribution. We noted two additional 
sources of variation that are known to have a large effect in biological systems. First, 
most cells (including the BHK-21 cells used herein) vary significantly in their size and 
state; this was expected to affect both the resources available for expression and the 
amount of founder population of replicons introduced during transfection.  Observing that 
single-replicon experiments showed a log-normal distribution of fluorescence, we 
modeled a cell variation factor V as a log-normal distribution: 
 
where N(0,σ) is a normal distribution with standard deviation σ.  We included this 
variation factor as a multiplier in the distribution of founder replicons, reflecting the 
hypothesis that larger cells are likely to take up proportionally more replicons: 
 
where fi is the number of founder replicons of the ith replicon, di is the partial dose of the 
ith replicon, and α is a parameterization constant fit previously in modeling the fraction 
of transfected cells. 
 The second major known source of variation is the stochasticity of biochemical 
processes when there are few molecules. In many cases, the number of founder copies of 
each replicon expected in each cell was quite low, in which case the first few replication 
events would have a large impact on the ultimate ratio of the two co-transfected 
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replicons. This can be modeled mathematically as a Polya Urn process
102
. The Polya Urn 
process considers an urn that begins with k balls, each of which has some color; for each 
of n iterations, a ball is drawn then replaced along with an extra ball of the same color, 
increasing the number of balls in the urn.  This model has the property that when the 
number of balls is small, the ratios can shift significantly, but as the process continues the 
ratios drift less, ultimately converging to a value distributed by a beta distribution 
parameterized on the initial set of balls. Applied to model our replicon systems, the colors 
are the replicon species, the initial balls are the founder copies, and the draw and 
replacement process is replication events, giving a model of: 
 
where pi is the proportion of the ith replicon following replication and Beta(x,y) is the 
beta distribution.  
 Combining these factors, we enhanced our earlier model of mean protein 
expression for single replicons to a model giving a distribution of expression for multiple 
replicon species: 
 
with the expression E(t,i) of the ith replicon at time t varying from the mean according to 
the cell variation factor and the distribution of the replicons’ proportions implied by the 
initial dose. Fitting this model against the set of 90%/10% titrations (to maximize 
observed variation), we obtained σ = 0.365. 
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 We validated our expression model and demonstrated how it can be used to 
engineer precision control of expression levels, by designing and predicting expression 
for a set of six three-replicon mixtures, with dosage levels and ratios ranging across 
approximately two orders of magnitude.  In all cases, our expression model provided a 
highly precise prediction of the observed value, with a mean prediction error of only 1.7-
fold.  With respect to individual mixtures, there was no significant difference in 
prediction quality. Prediction errors were lowest after approximately 24 hours, when the 
largest numbers of cells were fluorescing strongly and highest during the initial transient, 
when our model abstracted dose-dependence details. Means versus time for one of these 
mixtures are shown in Figure 3-3C.  Finally, the expression model precisely predicted not 
only the mean but also the distributions of fluorescence within each sample (Figure 3-
3D). 
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Figure 3-3 A Mathematical Model for Predicting Replicon Expression (A) Model fit for the 
rise toward saturation over the first 26 hours post-transfection (B) The mean predicted vs. 
measured expression for each color for all time/mixture combinations measured (mKate is 
red, EBFP2 is blue, and mVenus is green) (C) and (D) Examples of prediction detail: (C) 
Compares predicted vs. experimental evolution of mean expression for 360 ng mVenus, 360 
ng mKate, 1080 ng EBFP2 at 50 hours post-transfection, while (D) Compares predicted vs. 
experimental distribution of fluorescence values for the same mixture. All data were taken 
using Sindbis replicon in BHK-21 cells. Expression units are MEFL: Molecules of 
Equivalent FLuorescein. 
 
3.4 Limitations 
 The aforementioned work was performed using Sindbis replicons. Unfortunately, 
even with a noncytopathic variant, extended experiments with this replicon were 
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impossible due to toxicity and cell death. We transitioned from the use of a Sindbis 
replicon to a Venezuelan Equine Encephalitis (VEE) replicon that exhibited less 
cytopathicity and an associated increase in duration of expression. For the first 24 hours 
post-transfection, expression dynamics were very similar between Sindbis and VEE 
replicons and as a result we were able to reparametrize the mathematical expression 
model to accurately predict VEE replicons.    
 Because VEE replicon was less cytopathic, experiments could be extended up to a 
week. As shown in Figure 3-4, two VEE replicons were co-transfected: one expressing a 
green fluorescent protein, EGFP, and the other a red fluorescent protein, mKate. After 
three days, a gradual decrease in the percent of double positive cells was observed, as one 
of the two transfected replicons stopped expressing
5
. This behavior posed a serious 
problem for circuit design and functionality; regulatory devices would be competed out 
of a cell, rendering circuits inoperable and thus unsafe. Furthermore, with co-transfection, 
it can be difficult to ensure that each component of a genetic circuit or therapy is 
transfected into a given cell, particularly in vivo, which limits the therapeutic potential of 
multi-replicon circuits. To avoid these drawbacks, we began to pursue single replicon 
platforms that could be used to express multiple genes. 
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Figure 3-4. Long-Term VEE Expression using Co-transfection
5
 (A) VEE replicons expressing 
either mKate or EGFP were co-transfected into BHK-21 cells to observe the (A) Mean 
expression level and (B) Percent expressing each fluorescent protein over the course of 1 
week. Co-transfection results in a decrease in double positive cells after 3 days. 
 
3.5 Conclusions 
 We have demonstrated that unlike modRNA or pDNA, expression from replicons 
cannot be tuned in vitro using dose, as a result of replicon self-amplification and 
saturation of expression. Co-transfection can be used in a reliable and predictable manner 
to tune down expression of one or more replicons for the first few days post-transfection. 
However, for long-term, regulatory, or in vivo applications that require all replicon 
species to enter and remain in the same cell, co-transfection falls short. As a result, the 
remainder of our work will focus instead on various replicon-based platforms that can be 
used to produce and regulate the expression of multiple proteins from a single strand of 
RNA. 
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4. REGULATING MULTIPLE PROTEINS ON A SINGLE REPLICON 
 
4.1 Introduction 
 Single replicon circuits require multiple proteins to be expressed from a given 
RNA. This has been previously demonstrated using self-cleaving 2A peptides
98,103,104
, 
internal ribosome entry sites (IRES)
99–101
, and multiple subgenomic promoters 
(SGPs)
91,105,106
. Self-cleaving 2A peptides are an effective way to theoretically produce 
two proteins in equimolar amounts without fusing the two proteins together. Specifically, 
two proteins connected by a 2A peptide are translated together, after which the peptide 
self-cleaves, separating the proteins. However, cleavage efficiency and peptide scars can 
limit target protein functionality. Additionally, 2A peptides are not amenable to tuning 
the expression of two proteins relative to one another. 
 Internal ribosome entry sites are sequences that allow ribosomes to begin 
translation in a 5’-cap independent manner. IRESs have been successfully incorporated 
into replicons and IRES mutants have been identified to modulate their expression levels, 
making them excellent candidates for regulation of multi-gene expression. In our 
experience, however, replicon expression using an IRES is low (data not shown) and 
while we haven’t extensively pursed this course of study, we hypothesize that the 
secondary structure of the IRES is negatively affecting amplification. Other viruses that 
naturally contain multiple IRESs have been reported and would be more tolerable of this 
approach
99
.    
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 Alphavirus vectors employing multiple subgenomic promoters have been used for 
some time to express two heterologous genes. Yet, little has been done to independently 
regulate the expression levels of the proteins produced. To this end, we aimed to modify 
SGP strength. SGPs had been shown to be sequence dependent for some RNA viruses, 
including Sindbis virus
107,108
. While many of these studies were done to uncover minimal 
sequence requirements, we used this principle to create a library of SGPs of different 
strengths. 
 
4.2 Subgenomic Promoter Library 
 We generated a SGP library for VEE by truncating the full-length SGP from 
either the plus or minus side (Figure 4-1A). The SGP library was first tested in a tandem 
format to prevent any deletions to nsP4, as the base pairs comprising the minus side of 
the SGP are located in the coding region of the nsP4 protein. The first translational unit 
expressing mVenus, was held constant under the full-length -241/+30 SGP
91,109
. Our 
library of twenty-six truncated SGPs was placed before the second translational unit 
expressing mKate. Modulation of the second SGP alone can result in a 10-fold dynamic 
range in protein expression ranging from the weakest, -241/+3, to the strongest, -241/+15 
(Figure 4-1B, Appendix Figure 1). The experiment was repeated using mKate under 
control of the first SGP and mVenus under control of the second SGP, and provided the 
same outcome, proving these results were not protein dependent (data not shown). 
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A) Replicon Subgenomic Promoter Library 
 
B) Expression from the Second SGP 
 
 
Figure 4-1. Characterization of a Novel VEE Subgenomic Promoter Library (A) The wild type 
-241/+30 SGP consists of the 3’ region of nsP4 and the following 30 base pairs. Twenty-six 
truncations were made to either the plus or minus side of the SGP. (B) Because minus side 
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truncations would affect nsP4 function (primarily as an RNA-dependent RNA polymerase), 
the SGP library was tested using the second SGP in a tandem format. A subset of the tested 
SGPs is shown, representing a ten-fold range of expression. Results were normalized to 
either SGP30-mVenus or SGP30-mKate positive controls. Surprisingly, some SGPs 
expressed stronger than the wild type SGP30. Data were taken 24 hours post-transfection of 
1000 ng RNA in BHK-21 cells. The SGP library in its entirety is presented in the Appendix 
10-1.  
  
4.3 Positional Effects and Enhancing 3’Untranslated Regions (UTRs) 
 Another important finding was the effect of position on expression, i.e. expression 
from the second, more 3’-translational unit is always stronger than expression from the 
first if using SGPs of equal strength. While these positional effects could be utilized in 
circuit design to control protein expression, it would be essential to at least partially 
overcome this disparity. As a first attempt, an additional 3’UTR was inserted in between 
the translational units, as proximity to the 3’UTR has been shown to increase subgenomic 
transcription in other positive-strand RNA viruses
110,111
. By introducing a second 3’UTR, 
expression from the first translational unit increased eight-fold, confirming it is another 
means to control expression levels (Figure 4-2). 
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Figure 4-2 Introduction of Additional 3’UTRs to Enhance Positional Expression.  A 
supplementary 3’UTR sequence following the first translational unit increases expression of 
mVenus 8-fold when using two identical wild type -241/+30 SGPs. Data were taken 24 hours 
post-transfection of 1000 ng RNA in BHK-21 cells. Results were normalized to either 
SGP30-mVenus or SGP30-mKate positive controls. 
 
 Because a ten-fold range in expression was attainable by truncating only the plus 
side of the SGP, we were able to validate the results of our tandem experiment in a single 
SGP setting without risking mutations in nsP4 (hereafter SGPs will be referenced 
according to the number of base pairs on the positive side of the SGP, e.g. -241/+5 will 
be referred to as SGP5).  We chose five SGPs ranging in expression and placed them 
upstream of an mVenus reporter. The SGPs exhibited the same pattern of expression 
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strengths in a single SGP format, with a 16-fold range of expression (Figure 4-3). From 
these results obtained using one and two SGPs, we concluded that although the absolute 
strength of expression is context dependent and is contingent on the number of SGPs, the 
hierarchy of SGP strength remains unchanged.   
 
 
 
Figure 4-3. SGP Library Validation: Single SGP Replicons. The full dynamic range of the 
SGP library could be achieved using only plus side truncations, so the library was ported 
into a single SGP system. The same hierarchy between relative SGP expression was 
observed, with an increased range of expression levels, reaching 16-fold. Data were taken 24 
hours post-transfection of 1000 ng RNA in BHK-21 cells. Results were normalized to an 
SGP30-mVenus positive control. 
 
 During this experiment, we also found that cloning scars can have a profound 
impact on the range of expression of our SGP library. While cloning for the tandem SGP 
library left a minimal scar, initial cloning for the single SGP experiment was performed 
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using standard Gateway® cloning (Life Technologies) techniques
57
, resulting in a 
recombination scar that appeared to buffer expression and exhibit a low dynamic range 
(data not shown). The maximal range of 16-fold was only achieved when the SGP was 
followed immediately by a Kozak sequence. 
 
4.4 Multi-SGP Characterization 
 After establishing control of expression using an SGP library, additional 3’UTRs, 
and position on the replicon, we pursued a more in depth characterization of two and 
three SGP constructs. As we began testing the scalability of our approach in these 
formats, it quickly became apparent that a large collection of SGP combinations, with 
and without additional 3’UTRs, would need to be tested to adequately characterize the 
system and understand positional effects. Due to the large number of combinatorial 
assemblies and the need for scarless assembly, we adapted a Modular Cloning 
(MoClo)
58,59
 assembly strategy for replicons (Methods 8.1), used to generate all two and 
three SGP constructs discussed hereafter.  
 Using this MoClo-based cloning strategy, we were able to generate all 
permutations of two and three SGP constructs containing low (SGP5), midrange 
(SGP30), and high (SGP15) subgenomic promoter strengths, with and without additional 
3’UTRs. Figure 4-4 shows the two-SGP configuration with mVenus expressed under the 
first SGP and mKate expressed under the second SGP. In this setting, a 300-fold 
difference was observed between expression under the weakest SGP in the first position 
and the strongest SGP in the second position. As shown, this difference in positional 
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expression can be mitigated by strengthening the first SGP, weakening the second SGP, 
and by inserting an additional 3’UTR (Figure 4-4 and Appendix 10-2).  
 RT-PCR was used to quantify the relative levels of mVenus and mKate 
subgenomic RNA with and without an additional 3’UTR (Appendix 10-2). This study 
confirmed that the increase in expression resulting from an additional 3’UTR could be 
attributed to an increase in mVenus subgenomic RNA. Additionally, this experiment 
revealed that changes in SGP “strength” were primarily due to differences in the 
transcription of subgenomic RNA, rather than translation. These results are consistent 
with the internal initiation mechanism for subgenomic transcription, shown for SIN 
replicons (Figure 4-5)
112
. By truncating the SGP, the secondary structure of the initiating 
stem loop is altered, thereby increasing or decreasing its ability to facilitate transcription 
of the subgenomic RNA. This phenomenon has also been observed in other positive 
strand RNA viruses
113,114
.   
 These results also indicate that expression between the SGPs is not entirely 
independent (Appendix 10-2). The results for mVenus expression from the first SGP 
behave nearly independently of the second SGP, with a systematic increase in expression 
from weak (SGP5) to strong (SGP15), and slightly higher expression after including a 
3’UTR. While mKate expression shows this same general increase from SGP5 to SGP15 
under the second SGP, notice that the first SGP in front of mVenus also affects mKate 
expression, but not in a strength-dependent manner. We might hypothesize that higher 
mVenus expression may take resources away, leading to slightly lower mKate 
expression. However, when holding the second SGP constant, mKate expression is 
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inversely correlated to the length of the first SGP. While replicon position, additional 
3’UTRs, and SGP choice, in this order, are most important when determining expression 
level, but we may also need to consider how combinations of SGPs affect one another. 
 
 
Figure 4-4 Characterization of Constitutive Expression from Two-SGP Replicons. (A) All 
permutations of low (SGP5), midrange (SGP30), and high (SGP15) expressing SGPs with 
and without an additional 3’UTR sequence were assembled using an original replicon 
MoClo-based assembly strategy. Positional effects on expression dominate, but additional 
3’UTRs can partially mitigate this occurrence. The SGP library continues to operate in a 
predictable manner, even in this more complex framework. Data were taken 24 hours post-
transfection of 1000 ng RNA in BHK-21 cells. Results were normalized to either SGP30-
mVenus or SGP30-mKate positive controls. Comparison of RT-PCR data and fluorescence 
data can be found in the Appendix 10-2 
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Figure 4-5 Mechanism of Internal Initiation used by RNA Viruses
133
. Internal initiation of 
subgenomic transcription from a minus strand template is well documented and shown here 
for Sindbis virus. VEE contains a similar stem loop, and we consider this to be the SGP 
library’s mechanism of action. As we truncate the full-length SGP, the stability of this stem 
loop is either enhanced or diminished, leading to corresponding effects on transcription of 
subgenomic RNAs. The transcriptional effects of the SGP library were observed using RT-
PCR of two-SGP replicons and differences in subgenomic transcription correlate well with 
observed fluorescent expression levels (Appendix 10-2).  
 
 Constructs with three SGPs were created to validate the results observed with two 
SGPs (Figure 4-6). As expected, the third translational unit dominates expression. 
Modulating SGP strength and introducing additional 3’UTR sequences can be used to 
control expression, but only to a certain extent. Presumably, as more SGPs are added, 
expression from the 5’-most translational units will continue to decline, limiting the 
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scalability of this approach; limitations would be dependent on the necessary expression 
levels required for circuit function. However, we can now be confident in our ability to 
qualitatively predict relative constitutive expression levels based on position, additional 
3’UTRs, and SGP strength.  
 
 
Figure 4-6 Characterization of Constitutive Expression from Three-SGP Replicons. (A) All 
permutations of low (SGP5), midrange (SGP30), and high (SGP15) expressing SGPs with 
and without an additional 3’UTR sequence were assembled using an original replicon 
MoClo-based assembly strategy. Positional effects play an even larger role as more SGPs 
are added to a single replicon. Additional 3’UTRs still mitigate these effects, but the 
scalability of this method may become a limitation. As observed with two-SGP replicons, 
the SGP library continues to operate in a predictable manner, even in this more complex 
framework. Data were taken 24 hours post-transfection of 1000 ng RNA in BHK-21 cells. 
Results were normalized to SGP30-mVenus SGP30-mKate, or SGP30-EBFP2 positive 
controls.  
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4.5 Conclusions 
 We have created a novel SGP library and introduced additional 3’UTR sequences 
to regulate subgenomic transcription, and thus expression, from replicons. We can now 
predict relative expression levels of multiple constitutively expressed proteins in two- and 
three-SGP replicon configurations. These characterization data will advance multi-gene 
replicon-based therapeutics; now it will be possible to control relative dose. This will also 
inform the design of more complex replicon circuits. 
 
 
5. SMALL MOLECULE RESPONSIVE RNA CIRCUITS 
 
5.1 Introduction 
 Developing these RNA platforms for therapeutic use requires 1) tissue specific 
expression, 2) regulation of protein levels, and 3) temporal control of expression. 
Previously, other members of the Weiss lab have demonstrated that introducing micro-
RNA (miRNA) sites can elicit a tissue specific circuit response
5
. Using siRNAs in 
conjunction with RNA binding proteins (RBPs), they also generated multiple circuit 
topologies that responded to siRNA inputs, such as a modRNA toggle switch (Figure 5-
1). However, miRNA or siRNA regulation relies on RNA degradation, limiting 
reversibility and dynamic control once the circuit enters a target cell. Because these 
circuits rely on degradation of one or more circuit components, they must be co-
transfected, which weakens their potential for long term or in vivo applications, as 
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previously discussed. Here, we will develop a novel small molecule based regulatory 
motif that can be used to externally control expression from either modRNA or replicons 
without utilizing degradation. Rather than injecting a patient with siRNA, the goal would 
be to modulate circuit output using a pill taken orally. After creating novel small 
molecule based circuits, we will demonstrate that optimal circuit response is determined 
not only by the amount of small molecule, but also by tuning internal circuit components. 
 
 
 
Figure 5-1 Replicon Toggle Switch using siRNA-based Logic
5
. When siRNA-FF5 is 
introduced, the replicon expressing MS2-CNOT7-2A-EBFP is degraded, allowing 
expression of EYFP. L7Ae is also expressed in this state to repress any transcripts that 
avoid degradation and enhance stability of the toggle. When siRNA-FF4 is present, the 
replicon expressing L7Ae-2A-EYFP is degraded, allowing expression of EBFP and 
repression/deadenylation by MS2-CNOT7. 
 
5.2 Modified RNA 
5.2.1 OFF Switch 
 Small molecule responsive RNA circuits were first tested using modRNA because 
expression is proportional to the initial dose, allowing for systematic modulation of 
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protein levels. Small molecule responsive destabilization domains were fused to existing 
RBPs, such as L7Ae. L7Ae is a ribosomal protein from Archaeoglobus fulgidus that has 
been shown to bind RNA kink-turn (k-turn) motifs with high affinity, as well as k-loops 
to a lesser degree
115
. When k-turns are placed in the 5’UTR upstream of an open reading 
frame (ORF), L7Ae represses expression of the output protein. By fusing L7Ae to a 
destabilization domain engineered from E.coli dihydrofolate reductase (DDd)
116,117
, we 
created an OFF switch (Figure 5-2A). Upon addition of the FDA-approved small 
molecule trimethoprim (TMP), DDd-L7Ae is stabilized and represses the fluorescent 
output, mVenus. Without the cognate ligand, DDd-L7Ae is destabilized and degraded by 
the proteasome, resulting in mVenus expression. Here, we have also included a 2A-
mKate to monitor DDd-L7Ae expression levels. PEST sequences were fused to both 
reporter proteins to expedite turnover and prevent reporter buildup during the initial hours 
of translation when a functional amount of repressor may not exist
118
. 
 The OFF switch was tuned by adjusting the amounts of the repressor and the 
reporter with or without 10 μM TMP. For a given amount of reporter, increasing the 
amount of DDd-L7Ae decreased reporter expression in both states. This proved that even 
without the small molecule, DDd is not able to completely remove all L7Ae from the 
system. However, as the amount of reporter was increased, L7Ae that is not degraded had 
less of an effect, causing the ON-state to increase. Because L7Ae is a strong repressor, 
when it is stabilized by TMP, the OFF-state remained relatively constant, even with 
increased amounts of reporter. Taken together, this resulted in an increase in fold change 
as more DDd-L7Ae and mVenus are added (Figure 5-2B). The difference between the 
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maximum and minimum fold change, 9.3- and 1.4-fold, respectively, highlights the need 
for circuit tuning. With modRNA this tuning is straightforward, but with replicons it 
would have been impossible without the tools that we created to modulate expression. 
 
 
 
Figure 5-2 ModRNA TMP-Responsive DDd-L7Ae OFF Switches. Two modRNAs, expressing 
either mKate-2A-DDd-L7Ae or 2xK-turn-mVenus, were co-transfected at varying doses to 
tune expression levels. PEST sequences were fused to both reporter proteins to expedite 
turnover and prevent reporter buildup during the initial hours of translation when a 
functional amount of repressor may not exist
118
. mKate-2A-DDd-L7Ae was transfected at 
25, 50, 100, 250, 500, 750, and 1000 ng doses while 2xK-turn-mVenus was transfected at 
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200, 400, 600, 800, and 1000 ng doses. (A) When TMP is introduced, DDd-L7Ae is stabilized 
and represses mVenus. When TMP is absent, DDd-L7Ae is degraded, allowing mVenus 
expression. (B) Fluorescent output based on the initial amounts of DDd-L7Ae and mVenus 
transfected for both –TMP (blue) and +TMP (red) states. Note, data have been smoothed 
using Matlab for clarity (C) The fold change between the +TMP and –TMP states.  (C–D) 
In this switch, the mKate was coupled to DDd-L7Ae using a 2A sequence. Unexpectedly, 
mKate responded to TMP, as shown. Presumably this is as a result of incomplete cleavage 
by the 2A sequence, effectively fusing DDd onto L7Ae and mKate. While this had no effect 
on the function of the DDd-L7Ae OFF switch, it would affect the characterization of the 
following TetR-DDX6 ON switch. Thus, both TMP and doxycycline (Dox) were included in 
the + small molecule state for each characterization. Data were taken 12 hours post-
transfection of in BHK-21 cells. Results were normalized to 100 ng of either SGP30-mVenus 
or SGP30-mKate modRNA positive controls. 
 
5.2.2 ON Switch 
 In the same manner, TetR was used as a small molecule responsive RBP. TetR 
has already been shown to be responsive to tetracycline derivatives, including 
doxycycline (Dox), and while TetR is traditionally used for regulation of DNA circuits, 
RNA aptamers have been designed using systematic evolution of ligands by exponential 
enrichment (SELEX) to which TetR binds tightly
119
. In this case, TetR acts as an ON 
switch, repressing the output until Dox is present (Figure 5-3). Because a negligible Dox 
response was not observed for TetR alone expressed from modRNA, it was fused to dead 
box helicase 6 (DDX6) protein. DDX6 is a member of the CNOT pathway responsible 
for localizing transcripts to p-body regions of the cell, where translation is inhibited
120
. 
This TetR-DDX6 fusion increased the repressive capability of TetR, thereby enhancing 
the fold change in response to Dox. The ON switch was used to repress DDd-L7Ae-2A-
mKate-PEST, used previously, with knowledge that the two circuits would eventually be 
coupled. TetR-DDX6 followed same trends as DDd-L7Ae, more specifically, increasing 
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the amount of repressor and reporter resulted in a corresponding increase to the fold 
change. However, because TetR-DDX6 is a weaker repressor, a higher amount was 
needed to maintain a low OFF state. 
 
 
 
Figure 5-3 ModRNA Dox-Responsive TetR-DDX6 ON Switch. Two modRNAs, expressing 
either TetR-DDX6 or 1xTet-aptamer-mKate-2A-DDd-L7Ae, were co-transfected at varying 
doses to tune expression levels. A PEST sequence was fused to mKate to expedite turnover 
and prevent reporter buildup during the initial hours of translation when a functional 
amount of repressor may not exist
118
. TetR-DDX6 was transfected at 500, 1000, 1500, and 
2000 ng doses while 1xTet-aptamer-mKate-2A-DDd-L7Ae was transfected at 50, 100, 250, 
500, 750, and 1000 ng doses. (A) When Dox is introduced, TetR-DDX6 is inhibited allowing 
mKate expression. When Dox is absent, TetR-DDX6 is free to bind the Tet-aptamer and 
repress mKate. (B) Fluorescent output based on the initial amounts of TetR-DDX6 and 
mKate-2A-DDd-L7Ae transfected for both –Dox (blue) and +Dox (red) states. Note, data 
have been smoothed using Matlab for clarity (C) The fold change between the -Dox and 
+Dox states.  As explained in Figure 5-2, both TMP and Dox were included in the + small 
molecule state for each characterization. Data were taken 12 hours post-transfection of in 
BHK-21 cells. Results were normalized to 100 ng of an SGP30-mKate modRNA positive 
control. 
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 Expression for the OFF and ON switch was fit to the following Hill equation: 
𝑅𝑒𝑝𝑜𝑟𝑡𝑒𝑟 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 =  
𝛼 ∗ 𝑅𝑒𝑝𝑜𝑟𝑡𝑒𝑟(𝑛𝑔)
1 + (
𝑅𝑒𝑝𝑟𝑒𝑠𝑠𝑜𝑟(𝑛𝑔)
𝐾𝐼
)
𝑛 + 𝛽 
The slope of the standard curve using reporter only was used to calculate the α. Note that 
α differs between the mKate-2A-DDd-L7Ae and mVenus reporters because different 5’-
UTRs (1x-Tet-aptamer and 2x-K-turns, respectively) result in altered levels of 
expression. β was determined from background fluorescence. The inhibition constant, 𝐾𝐼, 
and the Hill coefficient, 𝑛 , were fit separately for the ON- and OFF-states using 
POLYMATH software. Changes in the inhibition constant reveal a much stronger, 9.2-
fold increase in DDd-L7Ae activity upon the addition of TMP, compared to a 2.4-fold 
increase in TetR-DDX6 after the removal of Dox (Table 5-1). Both KI values were larger 
for TetR-DDX6, revealing its weaker repressive capability.  
 
Table 5-1 Fitting Small Molecule Responsive modRNA Switches.  
 
Small 
Molecule 
KI n R
2 
DDd-L7Ae 
OFF Switch 
- 215 ± 28.7 0.672 ± 0.077 0.974 
+ 23.3 ± 3.07 1.02 ± 0.135 0.985 
TetR-DDX6 
ON Switch 
- 685 ± 48.9 0.985 ± 0.117 0.990 
+ 1646 ± 250 0.913 ± 0.235 0.983 
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5.2.3 Two-Output Cascade 
 The TetR-DDX6 ON switch and DDd-L7Ae OFF switch were coupled to 
generate small molecule responsive two-output cascades (Figure 5-4). Fifteen cascades 
were tested, covering a range of expression levels for TetR-DDX6 and DDd-L7Ae, while 
using only the highest amount of mVenus reporter. Coupling the two repressors resulted 
in modest increases in mVenus fold change compared to switches without TetR-DDX6. 
This increase was attributed to increased repression of DDd-L7Ae by TetR-DDX6, 
thereby increasing the mVenus ON state. This increase in fold change was more 
pronounced for lower doses of DDd-L7Ae, as TetR-DDX6 could better repress. There 
was also a slight trade-off between mKate and mVenus fold change. While the fold 
change of mKate increases as TetR-DDX6 increases, mVenus fold change decreases, but 
only minimally. By coupling these two small molecule responsive RBPs, we achieved a 
10.8-fold change for mVenus, but ultimately the maximal fold change is only constrained 
by the amount of modRNA that can be transfected. 
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Figure 5-4 ModRNA Small Molecule Responsive Two-Output Cascades. Three modRNAs, 
expressing TetR-DDX6, 1xTet-aptamer-mKate-2A-DDd-L7Ae, and 2xK-turn mVenus, were 
co-transfected at varying doses to tune expression levels. A PEST sequence was fused to 
both reporters as previously described. The dose of 2xK-turn mVenus was held constant at 
1000 ng because maximizing the dose of reporter resulted in the largest fold changes for the 
DDd-L7Ae OFF switch. TetR-DDX6 was transfected at 500, 1000, 1500 ng doses, as 2000 ng 
may have saturated the system for the ON switch. 1xTet-aptamer-mKate-2A-DDd-L7Ae 
was transfected at 100, 250, 500, 1000, and 1500 ng doses. (A) When Dox and TMP are 
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introduced, TetR-DDX6 is inhibited and DDd-L7Ae is stabilized, resulting in high mKate 
and low mVenus expression levels. When Dox and TMP are absent, TetR-DDX6 is free to 
bind the Tet-aptamer and repress mKate and DDd-L7Ae. DDd-L7Ae expression levels are 
further decreased by destabilization and degradation, resulting in high mVenus levels  (B) 
mVenus fluorescent output and (C) fold change based on the initial amounts of TetR-DDX6 
and mKate-2A-DDd-L7Ae transfected for both –TMP/Dox (blue) and +TMP/Dox (red) 
states. (D) mKate fluorescent output and (E) fold change. Data were taken 12 hours post-
transfection of in BHK-21 cells. Results were normalized to 100 ng of SGP30-mVenus and 
SGP30-mKate modRNA positive controls. 
 
5.3 Replicon 
5.3.1 OFF Switch 
 While control of constitutive expression from replicons is therapeutically relevant, 
small molecule responsive switches were created to introduce tighter regulation of 
protein levels using an external input. First, we created a simple ON switch, fusing DDd 
directly to an mVenus reporter (Figure 5-5), demonstrating small molecule regulation of 
protein levels from a replicon and validating the SGP library. While DDd could be fused 
to any therapeutic protein in this manner, it is important to note that DDd can decrease or 
compromise protein function. By using DDd-RBPs, we have increased the modularity of 
this platform and avoided these risks. Next, we created a replicon OFF switch using 
DDd-L7Ae. To maximize the output of our circuit, mVenus was placed under the second 
SGP. Unlike modRNA, where higher amounts of DDd-L7Ae increased circuit 
performance, preliminary tests revealed that high expression of DDd-L7Ae from a 
replicon resulted in unresponsive repression. We instead placed DDd-L7Ae under the 
first SGP without a UTR to decrease its expression, and observed the desired small 
molecule response. Data were taken at 24 and 48 hours post-transfection, showing an 
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increase in fold change with time. Again, the DDd-L7Ae switch variants agreed with the 
SGP library characterization. When DDd-L7Ae was degraded in the absence of TMP, 
mVenus expression levels were consistent with the weak (SGP5), midrange (SGP30), or 
strong (SGP15) SGP driving them. When TMP was introduced, although repression by 
DDd-L7Ae added another level of complexity for consideration, there remained a clear 
correlation between SGP strength and fold change, as more DDd-L7Ae was produced.   
 
A) 
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B) 
 
C) 
 
Figure 5-5 Replicon TMP-Responsive DDd-L7Ae OFF Switches. Replicon OFF switches were 
tuned by modifying the subgenomic promoter of either DDd-L7Ae or an mVenus reporter. 
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mVenus was driven from the second SGP to maximize output expression levels. As a very 
strong repressor, DDd-L7Ae expression was driven the first SGP without an additional 
3’UTR. (A) When TMP is present, DDd-L7Ae is stabilized and able to repress mVenus. 
When TMP is absent, DDd-L7Ae is degraded, allowing mVenus expression. The fluorescent 
outputs and fold changes are shown for (B) 24 and (C) 48 hours post-transfection of 1000 ng 
in BHK-21 cells. Using SGP5 (low), SGP30 (midrange), and SGP15 (high) SGP strengths 
before mVenus, we can see a predictable trend in the –TMP state when DDd-L7Ae is not 
present. The +TMP state is more complicated, as we must not only examine SGP 
interactions, but account for different DDd-L7Ae levels. Yet, we still observe a clear 
correlation between the strength of SGP driving DDd-L7Ae and fold change for this system.  
 
5.3.2 ON Switch 
 To create a more modular and therapeutically relevant ON switch, we created a 
three-SGP cascade of small molecule responsive RBPs. In the circuit topology shown, if 
TMP is present, DDd-L7Ae is stabilized, repressing TetR, and allowing for expression of 
mVenus-PEST (Figure 5-6). Dox was added in conjunction with TMP to further decrease 
TetR binding and increase expression of the ON state. From the modRNA and replicon 
OFF switch results, we hypothesized that the optimal circuit would have the reporter in 
Position 3 under SGP15 to maximize expression. DDd-L7Ae expression would be 
greatest in Position 2 under SGP15 and with an additional UTR. TetR driven from 
Position 1 would also need SGP15 and an additional UTR to achieve functional levels of 
expression. We screened a library of 96 circuit variants and the predicted circuit 
configuration resulted in the second highest fold change, 9.5-fold compared to 10-fold for 
the best performing circuit. As shown in Figure 5-6C/D, DDd-L7ae played a critical role 
in circuit performance. The OFF states for the 96 circuits were relatively consistent 
because TetR does not have a high range of repressive strength. However, higher ON 
states and fold changes were consistent with higher DDd-L7Ae. This high level of DDd-
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L7Ae expression was only possible by introducing additional 3’-UTR sequences. If we 
had not recognized the potential of 3’UTR sequences as a tool for expression 
enhancement and had performed this screen using the SGP library alone, the optimal fold 
change would be effectively halved. 
 
A)  
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B) 
 
C) 
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D) 
 
 
Figure 5-6 Replicon TMP/Dox-Responsive ON Switches. (A) 96-variants of a TMP/Dox-
responsive ON switch were created by modulating the SGP of TetR, DDd-L7Ae, and 
mVenus. mVenus was held under the third SGP to maximize output. TetR and L7Ae were 
placed under both the first and second SGP to maximize the range of the screen. When 
TMP is absent, DDd-L7Ae is degraded, allowing TetR to repress mVenus expression. When 
TMP is introduced, DDd-L7Ae is stabilized, repressing TetR, and allowing mVenus 
expression. Dox was also added in the +TMP state to further inhibit TetR.  The heat maps 
shown reflect the (B) OFF state, (C) ON state, and (D) fold change 48 hours post-
transfection of 1000 ng in BHK-21 cells. These heat maps reveal that high DDd-L7Ae levels 
are critical for circuit function. Both the ON state and fold change are primarily 
determined by these levels. Moreover, such expression levels would have been unattainable 
without introducing additional 3’UTR sequence, demonstrating its pivotal role in 
developing higher level RNA circuits.  
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5.3.3 Two-Output Cascade 
 The top four circuit configurations with TetR under the first SGP, as well as the 
top two configurations with TetR under the second SGP, were converted to two-output 
cascades by attaching a 2A-mKate sequence to TetR. With these alterations, mVenus fold 
changes ranged between 5.1- and 9.3-fold, while mKate fold changes ranged between 
1.2- and 3.9-fold, comparable to those achieved using modRNA (Figure 5-7). 
 
A) 
 
 
 
 
 
 
 
 
 
 
  52 
B) 
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C) 
 
 
Figure 5-7 Replicon Two-Output TMP/Dox-Responsive Cascades. (A) The two best 
performing constructs from Orientation 1 and the four best performing constructs from 
Orientation 2 of the small molecule responsive ON switches (Fig. 5-6A) were upgraded to 
express multiple fluorescent outputs. Specifically, a 2A-mKate was introduced, so that what 
was previously a non-expressing circuit state for mVenus would now express mKate. (B) 
mVenus expression levels and fold changes as well as (C) mKate expression levels and fold 
changes were recorded 48 hours post-transfection of 1000 ng in BHK-21 cells. These fold 
changes were nearly identical to those achieved using modRNA, a success considering this 
system avoids complications of co-transfection and is producing larger quantities of the 
output proteins. 
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5.4 Conclusions 
 We have demonstrated the ability to tune small molecule responsive switches 
using both modRNA and replicon platforms. Using novel parts, characterization data, and 
high throughput assembly we were able to generate complex replicon circuits, with 
comparable fold changes to modRNA, which do not rely on co-transfection. The ability 
to select between two proteins, and externally control dosage and timing of expression is 
therapeutically relevant. Extracellular control of precise protein levels is essential with 
regards to inter- and intra-individual variation, or for proteins with a narrow therapeutic 
window. By coupling these advancements in replicon engineering with the regulatory 
potential of small molecule responsive circuits, we have demonstrated the ability to 
create switches driven from a single RNA strand and have laid the groundwork for future 
replicon-based therapeutics. 
 
 
6. DNA Launched Replicons 
 
6.1 Introduction 
 After demonstrating that we could regulate expression of multiple constitutively 
expressed proteins and predictably design more complex circuits, we hoped to expand 
this framework to another platform: DNA launched replicons (DREPs)
10–12
. Though we 
have previously discussed the advantages of RNA replicons over DNA-based systems, 
DREPs showed potential for particular applications, such as antibody production in vitro. 
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Replicons, whether delivered as RNA or DREP, should generate higher levels of 
antibody than pDNA.  Yet, while RNA replicons have been shown to persist for up to 7 
weeks in vivo, they do not last this long in vitro. The goal of this project was to create an 
inducible DREP using existing DNA regulatory motifs, such as the Tet-OFF system 
previously described
3
. These DREPs would be stably integrated into a cell line. The 
circuits would remain OFF during the cell growth phase to prevent cytotoxicity. Once the 
optimal cell density was achieved, the DREP could be turned ON and express the desired 
antibody. Replicon engineering would be used to separately tune the heavy and light 
chains of the antibody to maximize production. 
  
6.2 Transcription Start Site and Terminator 
 A VEE DREP was developed using previously proven methods from literature. 
We included three relevant variables in our optimization: transcription start site, 
transcription terminator, and the introduction of a ribozyme before the terminator 
sequence. Although the end goal was to use an inducible promoter, we began by 
implementing the constitutive Cytomegalovirus (CMV) promoter. While most DNA-
based expression platforms do not require the ORF to be directly adjacent to the 
transcription start site, we presumed that any additional bases on the 5’-end of the 
transcribed replicon could affect self-amplification. Indeed, we found three different 
transcription start sites for the CMV promoter in the literature, differing by only a single 
nucleotide, and only one produced the bimodal expression typical of a constitutively 
expressing replicon (Figure 6-1A)
121–124
. This proved the sequence sensitivity of the 5’-
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end of the replication, which could be attributed to its strong secondary structure and 
involvement in RNA replication.  
 We also tested two commonly used mammalian terminators, BGH and SV40, and 
found no significant difference between the two. However, placing an antigenomic 
hepatitis delta virus (HDV) ribozyme before the terminator had a profound effect on 
replicability, as previously observed (Figure 6-2B)
124
. Without the ribozyme, 
transcription ends somewhere within the terminator sequence. As observed with the 
CMV promoter, this additional RNA sequence most likely disrupts the secondary 
structure of the replicon at the 3’-end, which has also been shown to influence 
replication. Conversely, with the 5’-cleaving ribozyme, only a single nucleotide is added 
to the poly(A) and the replication can proceed.  
 
A)  
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B) 
 
Figure 6-1 Creating a VEE DNA Launched Replicon. Three variables were tested before the 
VEE DREP was incorporated into the MoClo-based assembly strategy already in place for 
replicons. (A) First, a CMV promoter was chosen to drive the DREP because its 
transcription start site, while slightly contested in literature, was well characterized. Of the 
three CMV transcription start sites, only one resulted in highly efficient DREP expression. 
(B) Secondly, we tested two common terminator sequences used in mammalian synthetic 
biology, BGH and SV40. Addition of a ribozyme sequence was also used to prevent a 3’-scar 
after transcription from the plasmid. Both BGH and SV40 performed equally well, as 
shown, but without the antigenomic HDV ribozyme, express was far less bimodal. Data 
were taken 24 hours post-transfection of 250 ng of DNA in BHK-21 cells.   
 
6.3 SGP Library and Heavy-Light Chain Tuning 
 After optimizing the DREP, we adapted it to our existing MoClo-based assembly 
strategy. We were able to clone all two-SGP permutations of SGP5, SGP15, SGP16, and 
SGP30 (with the exception of SGP5/SGP16) expressing mVenus under the first SGP and 
mKate under the second SGP (Figure 6-2A). To maximize expression from the first 
translational unit, each of these constructs also contained an additional 3’UTR sequence. 
The SGP results were consistent with those collected using RNA, with the exception of 
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SGP30, which expresses at nearly the same level as SGP15 on a DREP. Additionally, the 
first SGP expresses at a much higher level from a DREP compared to RNA replicons. 
This difference could be attributed to the differences between replicon expression and 
constitutive DREP transcription. When the replicon enters the cell and begins self-
amplification, presumably all replicons within a given cell are synchronized, to an extent. 
However, because transcription of DREPs is continuous under the CMV promoter, there 
will be a mixture of replicons that have already been amplifying with those that were 
newly transcribed. The dynamics of these processes are not well characterized, but could 
account for the slight differences in relative SGP strengths. 
 The characterization using fluorescent reporters was then compared to ELISA 
data (performed by Ely Porter) to determine the optimal configuration for heavy and light 
chain expression of the S139 antibody, which inhibits influenza A viruses
125
. The same 
SGP configurations were used and the heavy and light chains were each placed under 
SGP1 and SGP2, or vice versa. In concordance with literature, the results obtained that 
the light chain must be more highly expressed in order to produce higher quantities of 
antibody. The amounts of antibody produced were also comparable to those produced 
when expressing the heavy and light chain from pDNA (data not shown). The advantage 
of the DREP is that this production could be generated from a lower initial amount of 
transfected DNA. In HEK293 cells, for example, antibody production increased when the 
dose was lowered (Figure 6-2B). The cells were believed to be healthier because a lower 
dose of DREP resulted in less replicon transcription from the plasmid, but replicon self-
amplification still produced increased amounts of antibody. 
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Figure 6-2 DNA Launched Replicon SGP Characterization and Heavy-Light Chain Tuning. 
(A) Constitutively expressing DREPs were created from all permutations of SGP5, 15, 16, 
and 30 with an additional 3’UTR to prove the portability of our regulatory framework to 
other replicon-based platforms. Characterization was carried out in C2C12 cells transfected 
with 250 ng DREP using both fluorescent proteins, as well as heavy and light chains. We 
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show that antibody production can be optimized by altering the relative expression of heavy 
and light chains, and the overall combined expression, in agreement with literature. (B) 
Furthermore, in HEK293 cells, we demonstrate that the advantage of a DREP, or any self-
amplifying system, is its performance at low doses. Here, a ten-fold lower dose results in 
comparable antibody production to a leading pDNA delivery vehicle. (Data taken in 
collaboration with Ely Porter) 
 
6.5 Conclusions and Future Work 
 We have developed a VEE DREP that is compatible with our parts library and 
assembly strategy. We have demonstrated that by tuning expression to optimize heavy 
and light chain levels, we were able to produce substantial amounts of antibody from a 
DREP. We will continue work using this platform by introducing inducible control to this 
system. As shown, lower amounts of DREP transcription are more beneficial for 
maintaining the health of the cell, as constant transcription of the replicon, followed by 
self-amplification, can be exceedingly cytotoxic. To this end, we must focus our efforts 
on maintaining minimal basal expression from the inducible DREP. The fold change 
between the OFF and ON states can be nominal because self-amplification will occur 
once any replicon is transcribed. After we have developed such regulatory mechanisms, 
we can stably integrate our DREP and control circuits into an antibody producing cell 
line.  
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7. Endoribonuclease-Mediated Split Self-Amplifying RNA 
 
7.1 Introduction 
 Another RNA platform explored was expression from a defective interfering (DI) 
RNA using a helper replicon. A defective interfering viral genome is produced when 
large portions of the genome are deleted due to recombination, leaving the remaining 
fragment defective and incapable of replication on its own. Instead, the DI genome must 
be complemented by a “helper” virus in order to replicate, interfering with the helper’s 
own replication through competitive inhibition. 
 A VEE DI RNA has previously been proposed and was adopted for this study
109
. 
To create this DI RNA, deletions were made to remove the 3’ portion of nsP1, the 
entirety of nsP2 and nsP3, and the 5’ portion of nsP4 (Figure 7-1A). In this way, the 
structural cloverleaf element formed by the 5’ of nsP1, which is involved in replication, 
remains intact, as well as the SGP located in the 3’ of nsP4. We chose this system 
because it lacks full-length non-structural proteins, specifically nsP2, which has been 
reported to be involved in negative feedback of the replication, leading us to hypothesize 
that this system would increase DI RNA expression while limiting the host cell immune 
response. 
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Figure 7-1 VEE Defective Interfering RNA. VEE DI RNA was generated by deleting the 3’-
region of nsP1, the entirety of nsP2 and nsP3, and the 5’-region of nsP4. Thus, a DI RNA is 
replication-incompetent without the addition of Helper RNA. If functional nonstructural 
proteins are available from another source, the DI RNA can amplify, since the 5’- and 3’-
UTRs, as well as the SGP, remain intact.  
 
7.2 Helper-Defective Interfering RNA Optimization 
 We first validated results reported by Kulasegaran-Shylini et al. that a G3A3 
mutation significantly increased DI RNA expression, despite previous findings that this 
mutation increases the ratio of genomic to subgenomic RNA in a full-length replicon 
(Figure 7-2A)
109
. We also increased DI RNA expression ourselves by optimizing the 
helper (Figure 7-2B). An optimal configuration for the helper was achieved by removing 
the positive side of the SGP and the entire ORF to prevent subgenomic translation, while 
introducing a G3A3 mutation to generate more genomic RNA and thus more non-
structural proteins. In addition, we were able to confirm that the truncated E1 structural 
protein, though not functional, was necessary in this configuration. This is most likely 
due to the RNA secondary structure it creates, which could facilitate the interaction 
between the 5’ and 3’ ends of the genome during replication126–128. 
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 We next verified that the SGP library carried over into this new platform and that 
co-transfection of a helper with multiple DI species behaved in a predictable manner 
(Figure 7-2C–E). As with co-transfected replicons, we observed constant total 
expression, with a linear response in expression based upon the initial ratio of the two DI 
species. Finally, we changed the ratio of helper to DI RNA, as multiple regimes of DI 
RNA interference have been reported against wild type viruses based on the amount of 
DI RNA present. Here, we see that while helper expression drops with decreasing initial 
dose, DI RNA expression does have a maximum that is dependent on the helper-DI RNA 
ratio.   
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D) 
 
E) 
            
 
Figure 7-2 VEE Defective Interfering RNA Studies (A) Confirmation that the G3A3 
mutation increases DI expression. A Helper-mKate was co-transfected with a DI-mVenus 
containing either base at position 3 (B) Helper optimization to maximize DI RNA 
expression. Here, we increased DI RNA expression by effectively increasing the available 
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nonstructural proteins for the DI RNA. A G3A3 mutation was implemented in the Helper 
RNA to increase genomic transcription and thus nonstructural protein translation. 
Additionally, the subgenomic ORF and the positive side of the SGP were deleted to prevent 
any competition from DI subgenomic transcription. Together, these modifications to the 
helper increased DI RNA expression to levels higher than the SGP30 positive control. (C) 
Optimization of Helper:DI ratio is critical for expression. If too much Helper RNA is 
transfected, low relative transfection efficiencies prevent adequate DI expression over the 
cell population. If too much DI RNA is present, the Helper RNA will not replicate efficiently 
due to competition for the nsPs, ultimately decreasing the expression from both RNAs (D) 
Expression of co-transfected Helper-EBFP, DI-mVenus, and DI-mKate revealed that 
similar to replicons, DI RNA will experience competition amongst one another. We use this 
competition to predictably control expression through relative transfected dose, noting that 
(E) total combined DI expression remains constant. Data were taken 24 hours post-
transfection in BHK-21 cells/ 
 
 The helper-DI system may not experience the gradual decrease of double positive 
cells observed with co-transfection of multiple replicons. If the DI RNA begins to out-
compete the helper, then the decrease in helper could lead to a decrease in non-structural 
proteins, and a subsequent decrease in DI RNA. If the helper begins to out-compete the 
DI RNA, then more non-structural proteins will be produced, and more DI RNA will be 
replicated. In addition, because DI RNA replication is dependent on the presence of the 
helper, by encoding the circuit output on DI RNA and regulatory elements on a helper, it 
is possible to ensure that the output will always be regulated, even using co-transfection. 
There are three possible outcomes: (i) the DI RNA enters the cell alone, will not 
replicate, and the protein will not be expressed, (ii) the helper enters the cell alone, 
replicates, but does not contain the output protein, and (iii) both the helper and DI RNA 
are co-delivered and replicate, resulting in the desired circuit function.  
 Unfortunately, as it stands, this circuit platform is not scalable to multiple DI 
RNA species, unless the DI RNAs are meant to function independently from one another. 
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Furthermore, in a preliminary experiment in vivo, no expression was observed using 
helper-DI RNA, most likely due to the inefficiency of co-delivery. To circumvent any co-
delivery issues, we propose a novel self-cleaving helper-DI RNA platform (Figure 7-4). 
In this system, the helper and DI RNA are delivered on a single strand of RNA. An 
endoribonuclease will be expressed shortly after the RNA enters the cell (we will discuss 
timing in Section 7.4). The two species will be cleaved inside the cell and replicate 
separately. Because DI RNA is relatively short (~1.7kb), this approach could be 
expanded to contain multiple DI RNAs. If successful, this approach could still utilize the 
SGP library to control expression levels and would permit both small molecule and 
degradation-based regulatory mechanisms. 
 
7.3 Csy4-Mediated Replicon Cleavage 
 Before constructing an intracellularly cleaving Helper-DI RNA, we had to find a 
suitable endoribonuclease that was effective enough to handle high amounts of self-
amplifying RNA. Csy4, is a CRISPR-associated endoribonuclease found in Pseudomonas 
aeruginosa, that recognizes a 28-nucleotide RNA repeat and cleaves between nucleotides 
20 and 21 (Figure 7-3A)
129,130
. To test the efficacy of Csy4, we built a simple, irreversible 
switch (Figure 7-3B). This switch first takes advantage of positional effects, with low 
mVenus expression under the first SGP and higher mKate expression under the second 
SGP. When Csy4 is added via co-transfection, mKate is cleaved off, resulting in a single 
SGP replicon and higher mVenus expression. An additional E1-3’UTR sequence and 
poly-A tail were inserted in between the ORFs to facilitate continued replication and 
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prevent degradation after cleavage occurs. Unfortunately, these additional sequences 
decreased mKate expression in the Csy4 (-) state. However, only wild type SGP30 was 
used and stronger SGPs may be able to counteract this effect. Regardless, we have shown 
that Csy4 was functional and could handle the load required in a self-amplifying RNA 
system. 
 
A) 
 
B) 
 
Figure 7-3 Csy4-Mediated Irreversible Switch (A) This irreversible switch takes advantage of 
positional effects to generate a fold change. If Csy4 is not introduced, the system behaves 
like a two-SGP replicon, mVenus expresses at low levels and mKate expresses at higher 
levels. If Csy4 is introduced, the mKate translational unit is cleaved off. The resulting single 
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SGP replicon expresses mVenus at high levels. (B) The results show that while the 
additional poly(A) sequence decreases mKate expression from the two-SGP system, 
resulting in a 3-fold change between states, we do see a marked increase in mVenus 
expression of 6-fold. These fold changes were achieved without any tuning from wild type 
SGP30 promoters, a sign of how robust this circuit topology could be. Data were taken 24 
hours post-transfection of 1000 ng of each construct in BHK-21 cells.  
 
7.4 Split Helper-DI RNA 
 After demonstrating the efficacy of Csy4, we developed a split Helper-DI RNA 
connected by a Csy4 recognition site (CRS).  Before Csy4 was expressed from this RNA 
using either an SGP or IRES, it was co-transfected from a replicon (Figure 7-4). As 
discussed for DREPs, amplification is dramatically affected by additional base pairs on 
the 5’ end of replicons, and we hypothesized that this observation also applied to DI 
RNA. To investigate this possibility, both wild type CRS and a minimal 3’-CRS were 
tested. The minimal 3’-CRS limits the cleavage scar to a single cytosine (nucleotide 21), 
which we presumed would not dramatically reduce expression, as a single guanine is 
added to the 5’-end of the replicon during in vitro transcription (IVT) to facilitate m7G 
capping.  
 As shown, using dead Csy4 to prevent cleavage yields low helper and DI RNA 
expression. Expression still exists at low levels because the helper-CRS-DI RNA acts as a 
modified two SGP replicon. When active Csy4 is added, cleavage occurs, resulting in 
higher expression of mKate from the helper because it no longer experiences a positional 
effect. Here, we also observed the effect of the scar left by the full-length CRS compared 
to the minimal 3’-CRS. The scar left by the full-length CRS makes DI RNA replication 
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very inefficient, leading to low mVenus expression from the DI RNA. Conversely, the 
minimal 3’-CRS results in substantial DI RNA expression.  
 
 
 
 
 
Figure 7-4 Csy4-Mediated Split Helper-DI RNA (A) Csy4 was employed to intracellularly 
cleave Helper-DI RNA. In these preliminary experiments, Csy4 was expressed on a co-
transfected replicon (B) A minimal Csy4 recognition site (CRS) is required to prevent a scar 
on the 5’ of the DI RNA. As observed with DREPs, 5’- scars dramatically reduce 
replication. Data taken 24 hours post-transfection of 1000 ng of each construct in BHK-21 
cells. 
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7.5 Towards a Helper-DI RNA High Sensor 
 One of the primary features of any nucleic acid based therapeutic should be cell 
specificity; whether using systemic or local administration, the therapeutic should only 
function in the target cells. Other members of the Weiss lab accomplished this using a 
combination of low and high miRNA sensors, delivered via pDNA circuits, and more 
recently modRNA (Figure 7-5)
5. These cell classifiers take advantage of each cell type’s 
unique miRNA profile. As shown, the cancerous HeLa cell line, with high miR-21 and 
low miR-141, miR-142(3p), and miR146a, can be differentiated from HEK293 and 
MCF7 cells. When miR-21 is present at high levels in HeLa cells, the mRNA expressing 
L7Ae is degraded, relieving repression of hBax, an apoptosis-inducing protein. To make 
the circuit more robust and specific to HeLa cells miR-141, miR-142(3p), and miR146a 
sites were included on the mRNA expressing hBax. In this way, cell types with high 
levels of any of these three miRNAs would degrade the hBax mRNA and survive, while 
HeLa cells would be killed. 
 
Figure 7-5 modRNA Cancer Cell Classifier (A) Using a set of high and low miRNAs specific 
to HeLa cells, a cell classifier was used to selectively target them for cell death via an 
apoptotic protein, hBax (B) The circuit was able to induce cell death in HeLa cells 
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comparable to constitutively expressed hBax, while cell death in HEK cells was only 
marginally above background. 
 
 As has been reiterated throughout this dissertation, the shortcomings of these 
circuits stem from co-transfection. These circuits must be co-transfected because they 
rely on RNA degradation to function. And while a miRNA sites can be used on a multi-
SGP replicon, it is currently impossible to build circuits of this complexity. Using the 
example above, we could include miR-141, miR-142(3p), and miR146a sites to make a 
low sensor, termed as such because when these target miRNAs are low, the output is 
visible, or in the ON state. However, there is presently no method to create a high sensor 
on a single replicon, in which the output is ON when miRNAs are high. A high miRNA 
induces degradation, and if a single replicon species is present, the entire replicon will be 
degraded and no output is possible.  
 The split Helper-DI RNA system offers a solution. This system can avoid issues 
associated with co-transfection prior to entering the cell, cleave itself intracellularly, and 
proceed to utilize degradation-based regulatory mechanisms. Thus, we aimed to create a 
single RNA, split Helper-DI RNA high sensor (Figure 7-6). 
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Figure 7-6. Schematic for a Split Helper-DI High Sensor. If Csy4 successfully cleaves the 
Helper and DI RNAs, siRNA-FF4 will only degrade the DI RNA driving mKate-2A-L7Ae. 
Without repression by L7Ae, mVenus will be expressed from the Helper RNA. If siRNA-
FF4 is not present in the system, the DI RNA will express high levels of mKate and L7Ae, 
and mVenus expression will be repressed.  
   
 Prior to proceeding, we tested a replicon-based high sensor to observe what fold 
changes could be expected from the split Helper-DI RNA sensor when functioning 
properly. Using siRNA-FF4 as an input, we co-transfected a replicon expressing an 
mVenus reporter with a replicon containing 4xFF4 sites and driving mKate fused to 
L7Ae (Figure 7-7). This topology exactly mirrors the proposed split Helper-DI high 
sensor. And indeed, when siRNA-FF4 is absent, high mKate and low mVenus are 
observed. Once siRNA-FF4 is introduced, the regulatory replicon species is degraded and 
mVenus is expressed highly. The switch-like nature of this system highlights the benefits 
of degradation-based regulatory mechanisms with repressive capabilities that are simply 
not possible with the small molecule responsive RBPs at the present. The fold changes 
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resulting from this system ranged between 80- to 260-fold for mVenus and 160- to 540- 
fold for mKate, as both L7Ae and siRNA-FF4 provide near perfect OFF states.     
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B) 
 
Figure 7-7 Co-transfected Replicon High Sensor. (A) A replicon high sensor was 
implemented by co-transfecting an mKate-G8-L7Ae replicon containing 4xFF4 sites with a 
2xK-turn-mVenus replicon. When siRNA-FF4 is introduced, the mKate-G8-L7Ae replicon 
is degraded, resulting in a switch from mKate to mVenus. (B) As shown in the 
representative plot, this circuit does have switch-like behavior, with very high fold changes 
and few cells expressing both mVenus and mKate together. Data were taken 24 hours post-
transfection in BHK cells. 
 
 Before attempting to create a high sensor using the split Helper-DI RNA system, 
we wanted to make a low sensor to prove that we could independently regulate the 
Helper and DI RNA (Figure 7-8). Without siRNA-FF4, both the Helper and DI RNA 
should express. Once siRNA-FF4 is added, if the system is cleaved, only the DI RNA 
expressing mVenus should be degraded. It is important to note that in all of the following 
experiments, siRNA-FF4 was transfected at the same time as all other RNA to most 
closely mimic the conditions that would occur if endogenous miRNA sites had been used. 
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For the first test, Csy4 was driven by a co-transfected replicon. The inherent delay in 
Csy4 expression attributable to RNA replication prior to translation (Figure 3-1) resulted 
in FF4 knockdown of the entire Helper-DI RNA. Not enough Csy4 was present early 
enough to cleave the Helper and DI RNA and prevent Helper-mKate knockdown. 
 
 
 
Figure 7-8. Split Helper-DI RNA Low Sensor with Co-transfected Csy4. A split Helper-DI 
RNA with 4xFF4 sites located on the DI RNA was co-transfected with a replicon expressing 
Csy4. The goal was for cleavage to occur and siRNA-FF4 to only degrade the DI RNA, 
while leaving the Helper RNA intact. As shown, both the Helper and DI RNA were 
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degraded by siRNA-FF4. Moreover, the low remaining levels of expression were similar to 
those when co-transfected Csy4 was replaced by EBFP, suggesting Csy4 was having no 
effect in this experimental setup. Data were taken 24 hours post-transfection of 1000 ng of 
each construct in BHK-21 cells.  
 
 To express Csy4 earlier and to avoid co-transfection, Csy4 was placed under an 
encephalomyocarditis (EMCV) IRES located on the Helper RNA (Figure 7-9)
131
. 
Because Csy4 is translated and cleaves immediately, we were able split the Helper and 
DI RNA before siRNA-FF4 knockdown, resulting in high mKate expression. mVenus 
behaved as expected, decreasing 68-fold when siRNA-FF4 was introduced, but the 
expression levels decreased significantly. This low expression level may be preferable, 
specifically for classifiers with a “kill-switch” output as described above. For example, 
hBax requires only low amounts to have the desired phenotypic output. More important is 
the low background, preventing unwanted cell death, which this circuit could provide.  
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Figure 7-9 Split Helper-DI RNA Low Sensor with IRES-Csy4. By expressing Csy4 earlier 
during replication using an IRES, we successfully rescued the Helper RNA from 
degradation by siRNA-FF4. However, DI RNA expression, even in the absence of siRNA-
FF4 was very low, presumably due to a lack of capping capability early in replication. 
While we have moved a step in the right direction and the circuit is functioning, it remains 
to be seen whether this is a practical amount of DI RNA expression. Note that in the 
proceeding experiment EBFP is used as a transfection control to ensure that the amount of 
nonstructural proteins available to the DI RNA does not change significantly between 
constructs with an IRES-Csy4 and those requiring co-transfection of Csy4. Data were taken 
24 hours post-transfection using 1000 ng of each construct in BHK-21 cells   
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7.6 Future Work 
 While the aforementioned circuit could be relevant for specific applications, we 
aim to create a more robust miRNA-responsive split Helper-DI RNA platform. We 
speculate that early Csy4 cleavage is preventing capping of the DI RNA by nsP1
132,133
. 
Because Csy4 cleaves earlier during replication when expressed from an IRES, there is 
either not enough nsP1 present or this functionality is not occurring at the current stage of 
replication. If the DI RNA is left uncapped, even for a short time, it will be degraded by 
the host cell. This would explain the low levels of mVenus observed without the addition 
of siRNA-FF4. 
 In summary, when Csy4 is immediately translated from an IRES, the DI RNA 
cannot be capped effectively, reducing output. Conversely, when Csy4 expression is 
delayed via co-transfection, siRNA-FF4 has already begun to degrade the entire uncut 
Helper-DI RNA. To resolve these issues, we decided to build a delay for FF4 site 
presentation into the replicon. As a first attempt, we simply rearranged the FF4 sites, so 
they would be presented in the minus strand. We hoped that the delay in minus strand 
generation would be enough for more Csy4 to cleave before siRNA-FF4 became active. 
However, placing FF4 sites in the minus strand did not elicit any knockdown, removing 
this possibility. 
 Instead, we decided to move the entire DI RNA to the minus strand (Figure 7-10). 
Self-cleaving ribozymes in the minus strand would cleave out the DI RNA, eliminating 
the need to control Csy4 levels. We could not use ribozymes previously because if 
encoded in the plus strand, the ribozymes would cleave during IVT prior to transfection. 
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If successful, upon entry into a cell, the FF4 sites on the Helper-DI RNA will be hidden. 
Once minus strand production begins, the ribozymes will cleave out the DI RNA. At this 
stage, enough functional nsP1 should be present to cap this RNA. The DI RNA will then 
act as a plus strand RNA, replicating if siRNA-FF4 is absent or degrading if siRNA-FF4 
is present. This platform could be modularized to include multiple DI RNAs, each tuned 
using SGPs and regulated with miRNA sites, to create complex circuit functions from a 
single transfected RNA.        
 
 
Figure 7-10 Flipped Split Helper-DI RNA Low Sensor. Timing of Helper-DI RNA cleavage is 
a major challenge for the development of this split Helper-DI platform. If cleavage occurs 
too late, siRNA or miRNAs will degrade both the Helper and DI RNA. If cleavage occurs 
too soon, using IRES Csy4, the DI RNA is not adequately capped and expression suffers. 
Here, we proposed two related architectures to insert a delay into DI RNA cleavage, while 
hiding the FF4 sites. In the first design, IRES-Csy4 is used to generate Csy4 early in 
replication. However, because the DI RNA and Csy4 recognition sites are encoded in the 
minus strand, they are not available to Csy4 until later in replication. In the same way, 
ribozymes can be used to extract the DI RNA by only when minus strand RNA is being 
transcribed. Once the DI RNA is excised, we expect enough functional nsP1 for capping to 
take place. If successful, this system would allow for high DI RNA expression when siRNA-
FF4 is absent, but would retain regulatory functions if siRNA is introduced.   
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7.7 Conclusions 
 DI RNAs offer unique advantages for constructing RNA circuits. Their reliance 
on Helper RNA for replication could overcome problems associated with co-transfection, 
since both the Helper and DI RNA are required for DI RNA expression. The small size of 
DI RNA is essential when coupling multiple self-amplifying RNAs onto a single strand. 
We have demonstrated that we can couple a Helper and DI RNA onto a single strand, 
cleave them apart intracellularly using an endoribonuclease, and that they then will 
subsequently replicate individually. While degradation-based regulation of the cleaved 
Helper and DI RNA is now possible, more work will be done to maximize the 
functionality of this novel platform.   
 
 
8. Conclusions 
8.1 Synopsis 
 RNA replicons are a potent gene delivery vehicle, providing a higher expression 
levels over a longer time than many competing modalities. However, the lack of control 
over replicon expression has led to safety concerns and prevented its widespread use. 
Herein, we have described four different modes of replicon regulation: 1) competition via 
co-transfection, 2) sequence-level modulation using position, additional 3’UTRs, and a 
novel SGP library, 3) small molecule responsive RBPs, and 4) degradation based 
mechanisms, such as siRNA or miRNA. We have developed a regulatory framework that 
can be used to create RNA-only circuits and is transferable to other existing replicon-
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based platforms, such as DREPs and DI RNA. Finally, we have proposed a novel split 
Helper-DI RNA platform with the potential to drive even more complex circuits by using 
combining multiple modes of regulation.    
 
8.2 Tuning Replicon Expression 
 As a necessary first step in the development of replicon regulation, the dynamics 
of replicon expression were elucidated and quantified by completing a single replicon 
time course. From this study, it was apparent that unlike pDNA or modRNA, replicon 
expression levels could not be modulated using the initial transfected dose. Instead, 
competition was used to tune expression levels down by co-transfecting multiple replicon 
species into a given cell. After this strategy yielded positive results for two co-transfected 
replicons, a mathematical model was generated to predict expression levels from any 
number of co-transfected replicon species over time, and was validated by conducting a 
time course of three co-transfected replicons.   
 
8.3 Multi-Subgenomic Promoter RNA Circuits 
 While predictably controlling expression levels from co-transfected replicons was 
useful for short in vitro studies, it was proven to be ineffective for long term regulation 
because cells began to lose one or more of the co-transfected replicon species after three 
days. As an alternative, sequence-level elements were discovered that could modulate the 
expression of multiple proteins from a single strand of self-amplifying RNA. A novel 
SGP library was developed to control expression levels. In doing so, the effect of position 
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on relative expression became evident. Specifically, more 3’-translational units expressed 
higher than 5’-translational units. To partially overcome this positional dependence on 
expression, additional 3’UTR sequences were introduced between the translational units. 
The 3’UTRs increased expression by enhancing subgenomic transcription of the more 5’-
translational unit. After elucidating the parameters involved in control of multi-SGP 
replicons, a MoClo-based assembly strategy was developed to fully characterize two- and 
three-SGP replicons. These constructs behaved in a predictable manner, instilling 
confidence that using these parts, we could intelligently design more complex multi-SGP 
circuits.   
 
8.4 Small Molecule Responsive RNA Circuits 
 While we had demonstrated that sequence-level replicon parts could control 
constitutive expression, for many applications external control of expression is 
considered safer and more desirable. To this end, we utilized existing small molecule 
responsive RNA binding proteins, such as TetR, or developed novel fusions of 
destabilization domains and well-characterized RBPs, such as DDd-L7Ae. Using TetR or 
DDd-L7Ae in conjunction with circuit tuning, we were able to optimize ON and OFF 
switches, respectively, for both modRNA and replicon platforms. These switches were 
coupled to create small molecule responsive, two-output cascades. Notably, using 
sequence-level regulatory motifs, we were able to tune the replicon circuits and achieve 
fold changes similar to those elicited from the same circuits driven from modRNA.   
 
  85 
8.5 DNA Launched Replicon 
 Generating single replicon circuits proved the efficacy of the replicon parts 
toolbox when creating more complex designs. However, we also wanted to prove that 
these genetic parts were transferable to other replicon platforms and viable for therapeutic 
applications. Here, we used position, additional 3’UTRs, and SGP choice to characterize 
a two-SGP DREP, driving expression of either fluorescent proteins or heavy and light 
chains. Relative expression of the fluorescent proteins differed slightly from RNA, but 
still obeyed the same general principles and hierarchy with regard to SGP strength. 
ELISA results after heavy and light chain production corroborated existing notions that 
slightly more light chain is preferable when producing antibodies. From this 
optimization, we were able to produce equivalent quantities of antibody from a ten-fold 
lower dose compared to pDNA.  
 
8.6 Intracellularly Cleaved Self-Amplifying RNA 
 Self-cleaving Helper-DI RNA may be the future of replicon-based circuits 
delivered via a single RNA strand. We have proved that two- and three-SGP replicons 
can effectively produce high levels of proteins and create complex genetic circuits, but 
they do have limitations. Positional effects play an everincreasing role as more SGPs are 
added. Furthermore, these circuits cannot benefit from the cell classifying capabilities 
and high fold changes resulting from miRNA and siRNA regulation. Through successive 
tests of Csy4-mediated split Helper-DI RNA, we have arrived at two designs. By 
coupling either Csy4 recognition sites or ribozymes with DI RNA encoded in the minus 
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strand, we aim to create the first high sensor encoded on a single strand of RNA. If 
successful, this pioneering platform for RNA circuits could employ multiple modes of 
control, including the SGP library, small molecule responsive RBPs, and degradation-
based mechanisms, without the limitations associated with co-transfection. 
 
 
9. Methods 
 
9.1 Replicon Cloning Strategy 
 Each translational unit was divided into three parts: an SGP, ORF, and 3’-UTR. 
Each of the parts was placed in a Level 0 vector and flanked by BsaI recognition sites 
(Figure 9-1). BsaI, a Type IIS restriction enzyme, recognizes a sequence and cleaves 
downstream of its recognition site, allowing for scarless assembly. The Level 0’s are 
combined into a Level 1 destination vector to form a single translational unit, using 
conserved sequences in between the SGP, ORF, and 3’UTR. Finally, Level 1’s are 
combined into the replicon backbone using a second Type IIs enzyme, SapI, to form the 
final Level 2 product, a functional multi-unit replicon. This assembly strategy is 
extremely efficient, with respect to both reaction time (1 hour at 37C, 5 minutes at 50C, 5 
minutes at 80C) and percentage of correct clones (~75% correct by picking one colony, 
~100% correct by picking 3 colonies), and was used to generate the majority of the multi-
SGP replicons discussed in this work. 
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Figure 9-1. Schematic of MoClo-based assembly strategy for multi-unit replicons 
 
 Figure 9-2 is a sequence level description of the Replicon MoClo Assembly, 
beginning with the various Level 0 destination vectors. These Level 0 destination vectors 
were made for use with either of the following Type IIS enzymes: SapI or BbsI. SapI has 
a 7-base pair (bp) recognition site and a 3-bp overhang while BbsI has a 6-bp recognition 
site and a 4-bp overhang. Typically, we mutate BsaI and SapI sites within any new ORFs 
to make the Level 01 and Level 12 reactions more efficient, respectively, but this is 
not required if a final ligation step is added to the MoClo reaction. Our SGP library and 
the VEE 3’UTR do not contain recognition sites for either of these enzymes, so this 
problem most commonly arises with ORFs, but this should be considered when 
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incorporating any new part, such as an aptamer sequences or modified 3’UTRs. The 
Level 0 destination vectors contain Ampicillin resistance, with the BsaI site in the AmpR 
gene mutated to facilitate a more efficient Level 01 reaction. In addition, we have 
mutated the BsaI site in the ccdB gene, allowing us to also create Level 0’s via a 
digest/ligation reaction with BsaI; this is very efficient because the ccdB gene will kill the 
cells that do not receive the insert. Typically this is how we introduce new ORF because 
if flanked by BsaI sites the ORF can be incorporated into Level 0 and Level 1 destination 
vectors at the same time. 
 Each Level 0 destination vector is shown below, with an example of how to insert 
a given unit (SGP, ORF, or UTR). 
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Figure 9-2. Sequence-level description of Level 0 destination vectors 
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Once a library of SGPs, ORFs, and UTRs is established, one can combine Level 0’s to 
make Level 1’s, which are individual translational units. However, as we have shown, 
position on the replicon has a significant effect on expression, so the Level 1 destination 
vectors must also contain information on the translational unit’s position in the final 
construct. In addition, some units will have 3’UTR sequences while others will not. 
These constraints leave us with the following seven Level 1 destination:  
 
  
 
What position will the 
construct be? 
P1 P2 P3 
Will there be a 3’UTR? Will there be a 3’UTR? 
No Yes No Yes 
Use TW323 
Will this construct be 
used in Level 2’s with 
more than 1 unit? 
Will this construct be 
used in Level 2’s with 
more than 2 units? 
Use TW326 
Use TW328 
Yes (tandem or triple 
SGP constructs) 
No (single 
unit) 
Use TW322 
Use TW324 
Yes (triple SGP 
constructs) 
No (for 
tandems) 
Use TW325 
Use TW327 
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Figure 9-3 Sequence-level description of Level 1 destination vectors 
 
 Notice that to modify a single-SGP replicon, this strategy is cumbersome, 
requiring two rounds of reactions: first combining SGP, ORF, and E1-3’UTR into a 
Level 1 and then inserting this single translational unit into a Level 2. To speed up 
cloning for single gene replicon, we have also created Level 0S. These Level 0S can be 
combined directly into a Level 2 to test the function of a specific ORF before more in 
depth characterization. After such characterization, the Level 0S can easily be transferred 
to Level 0 (using SapI) for use with the MoClo strategy above. Note that Level 0S have 
Kanamycin resistance similar to Level 1 vectors.   
 Finally Level 1 or Level 0S plasmids can be combined into a Level 2 replicon 
backbone (Figure 9-4). Note that all replicon-based systems require SGP, ORF, or 3’UTR 
modulation and were created in this way, including DREP and split Helper-DI RNA 
platforms.  
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Figure 9-4. Sequence-level description of Level 2 destination vector 
 
9.2 RNA Generation 
9.2.1 Sindbis Replicon 
 All Sindbis constructs were created from pSINV-EYFP using standard molecular 
cloning techniques. The replicon itself originated from the TE12 strain of Sindbis and 
was altered to contain the previously characterized, less cytopathic P726S mutation in 
nsP2. The plasmids were linearized using SacI prior to run-off in vitro transcription using 
the mMESSAGE mMachine® SP6 Kit (Life Technologies). The resulting RNA was 
purified using the RNeasy® Mini Kit (Qiagen) before transfection. 
 
9.2.2 VEE Replicon 
 VEE replicon derived from the TC-83 strain, containing an A3G mutation as well 
as a Q739L mutation in nsP2, was built in the Weiss lab. The plasmids were linearized 
using I-sceI (NEB) prior to run-off in vitro transcription. IVTs were performed using 
either the mMESSAGE mMachine® T7 Kit (Life Technologies) or the MEGAscript® T7 
Transcription Kit (Life Technologies). The resulting RNA was purified using either the 
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RNeasy® Mini Kit (Qiagen) or lithium chloride precipitation. If the MEGAscript® T7 
Transcription Kit was used, purification was followed by denaturation of the RNA at 
65
o
C and enzymatic (Cap1) capping of the RNA using the ScriptCap 2’-O-
methyltransferase Kit (Cellscript) and ScriptCap m7G Capping System (Cellscript). A 
second purification using either the RNeasy Mini Kit (Qiagen) or lithium chloride 
precipitation was required prior to transfection. Unless otherwise stated, transfections 
were performed with 1 μg of RNA per sample. If siRNA regulation was required, 
siRNAs (IDT) were co-electroporated at a final concentration of 10 nM along with 
replicon RNA.  
 
9.2.3 Modified RNA 
 A template DNA for IVT was generated by PCR, using a forward primer 
containing T7 promoter and binding the plus side of the SGP, and a reverse primer 
binding the 3’UTR. To remove plasmid DNA, products were subjected to DpnI (NEB) 
digestion and purified. IVTs were performed using MegaScript T7 kit (Life 
Technologies) under a modified condition, in which UTP was replaced by N1-
Methylpseudouridine-5'-Triphosphate (TriLink BioTechnologies). Transcripts were 
treated with Turbo DNase (Life Technologies) for 15 min at 37°C and purified using 
lithium chloride precipitation. Resulting mRNAs were enzymatically (Cap1) capped 
using the ScriptCap 2’-O-methyltransferase Kit (Cellscript) and ScriptCap m7G Capping 
System (Cellscript). Capped mRNA transcripts were subsequently polyadenylated using 
the A-Plus
TM
 Poly(A)-Tailing Kit (Cellscript) according to the manufacturers’ protocol. 
  97 
A second purification using lithium chloride precipitation was performed prior to 
transfection. 
   
9.3 Cell Culture and Transfection 
 All RNA transfections were conducted in BHK-21 cells (a kind gift from Dr. 
James H. Strauss) cultured in EMEM (ATCC) supplemented with 10% FBS (PAA) at 
37
o
C and 5% CO2. BHK-21 cells at approximately 70% confluence were electroporated 
using the Neon
™ 
Transfection System (Life Technologies) following cell line 
optimization, according to the manufacturers’ instructions. In general, for a 10 μl 
transfection into a single well of a 24-well plate (Corning), approximately 100,000 cells 
were electroporated. In general, 1 μg of RNA was transfected per 100,000 cells unless 
otherwise stated. Experiments were performed in either 24- or 96-well plates (Corning) 
with the plating density scaled accordingly.  
 DREP transfections were conducted in either BHK-21 cells as above or in 
HEK293 or C2C12 cells cultured in DMEM (ATCC) supplemented with 10% FBS 
(PAA) at 37
o
C and 5% CO2. HEK293 or C2C12 cells were transfected using Viafect
TM
 
Transfection Reagent (Promega) according to the manufacturers’ instructions using 
between 10–250ng of plasmid DNA. 
 
9.4 Flow Cytometry 
 Cells for each time point were washed with 1x PBS, trypsinized, and resuspended 
in 1x PBS. Flow cytometry was performed using the BD LSRFortessa
™
 Flow Cytometer 
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System (BD Biosciences), equipped with 405, 488, and 581 nm lasers. FACSDiva 
software was used for initial data collection. We collected 10,000–30,000 events per 
sample for 24-well plates and 2,000–10,000 events per sample for 96-well plates. 
Fluorescence data were acquired with the following cytometer settings: 488 nm laser and 
530/30 nm bandpass filter for EYFP/EGFP, 561 nm laser and 610/20 nm filter for mKate, 
and 405 nm laser, 450/50 filter for EBFP. Data analysis was performed with FlowJo V10. 
For all fluorescence assays, populations containing live, single cells were first determined 
based on forward and side scatter. Replicon and modRNA electroporation typically 
exceeds 90% transfection efficiency and therefore all live, single cells were taken into 
account for calculating mean or geometric mean output fluorescence, unless otherwise 
stated. Representative flow plots for all circuits are included in the Appendix. 
 
9.5 Fluorescent Microscopy 
 Fluorescence microscopy images of live cells containing the small molecule 
responsive, two-output replicon cascades were taken 48 hours post-transfection in 24-
well plates using Zeiss Axiovert 200 microscope and Plan-Neofluar 10x Ph1 objective at 
100% power. The filters used were 500/20 (excitation) and 535/20 (emission) for 
mVenus and 565/30 (excitation) and 620/60 (emission) for mKate. Exposure times were 
3ms for the bright field, 200 ms for mVenus, and 1000 ms for mKate. Data collection and 
processing were performed using AxioVision (Zeiss) and ImageJ software. 
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9.6 RNA Extraction and qPCR 
 RNA from cells transfected with two-SGP replicons constitutively expressing 
mVenus and mKate was extracted 24 hours post-transfection using the Direct-zol
TM
 RNA 
Miniprep Kit (Zymo Research). 500 ng of RNA was reverse transcribed with the 
SuperScript® III Reverse Transcription Kit (Invitrogen). Resulting cDNA was subjected 
to RT-PCR using the KAPA SYBR FAST Universal 2x qPCR Master Mix (Kapa 
Biosystems). RT-PCR was performed on a Mastercycler ep Realplex (Eppendorf). 
Primers were designed to bind within the 5’-end of nsp4, mVenus, and mKate. The 
relative amounts of each were normalized to GAPDH on a per sample basis. Here, the 
amounts of mVenus and mKate included both the genomic and subgenomic RNA. The 
amount of nsP4 was subtracted from these values to determine the relative amount of 
subgenomic RNA for either mVenus or mKate. 
Primer sequences: 
mVenus-qPCR-F GCACAAGCTGGAGTACAACTAC 
mVenus-qPCR-R GATGTTGTGGCGGATCTTGAA 
mKate-qPCR-F GATCCAAGAAACCCGCTAAGAA 
mKate-qPCR-R CTGCTCGACGTATGTCTCTTTG 
nsP4-qPCR-F GTGTTGGAGAGGACCGAATTG 
nsP4-qPCR-R CTGTTAGCAGGTGTGGGATTT 
GAPDH-qPCR-F GAACGGGAAGCTTGTCATCA 
GAPDH-qPCR-F GCCAGTAGACTCCACAACATAC  
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10. Appendix 
 
Figure 10-1 Complete SGP Library 
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Figure 10-2 Complete Two-SGP Characterization 
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